

ASCO® Breakthrough™

PROGRAM

GATHERING THE ONCOLOGY COMMUNITY IN ASIA

June 25–27, 2026

Raffles City Convention Centre | Singapore & Online

WiFi Network: ascobt26

Password: ascobt26

Password is case sensitive

asco.org/bt-program

#ASCOBT26

Co-Hosts

ASCO®
ASSOCIATION FOR CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

Singapore
Society of
Oncology 

Contents

Committees	4
Merit Award Recipients	6
Feedback and Certificates	7
Attendee Resources	8
Program at a Glance	9
Program by Day	12
Poster Directory	18
Exhibitor Directory	36

SAVE THE DATE:

2027 ASCO Breakthrough

June 24-26, 2027 | Raffles City Convention Centre | Singapore | breakthrough.asco.org

Committees

Program Committee Leadership

Yun Yen, MD, PhD, FASCO—Chair

Taipei Medical University

Roselle De Guzman, MD, FASCO—Chair-Elect

Manila Central University

Melvin Chua, MBBS, PhD, FASCO—Past Chair

National Cancer Centre Singapore

Eileen Yi Ling Poon, MD—Co-Host Representative

National Cancer Centre Singapore

Jun Ma, MD—Asia-Pacific Regional Council Representative

Sun Yat-sen University Cancer Center

Program Committee

Takayuki Yoshino, MD, PhD

National Cancer Center Hospital East

Hironobu Minami, MD, PhD

Kobe University

Herbert H. Loong, MBBS, FRCP, FASCO

Chinese University of Hong Kong

Joon Oh Park, MD

Samsung Medical Center

Naoto Ueno, MD, PhD

University of Hawai'i

David Goldstein, MD, FRACP, MBBS

Prince of Wales Hospital in Sydney

Dawn Q. Chong, MPH, MBBS, MRCP

National Cancer Centre Singapore

Kimmie Ng, MD, MPH, FASCO

Dana-Farber Cancer Institute

Sonia Mathai, MD, MPH

Tata Medical Center

Annie Wong, MBChB, PhD

Peter MacCallum Cancer Centre

Sue Yom, MD, PhD

University of California San Francisco

Desmond Yip, MBBS

The Canberra Hospital

Natasha Leigh, MD, FRCP, FASCO

Princess Margaret Cancer Centre

Joe Yeong Poh Sheng, MBBS, PhD

Agency for Science, Technology and Research (A*STAR) and
Singapore General Hospital

Danielle Bitterman, MD

Dana-Farber Cancer Institute

David Lee, MBBS, MMed

Sunway Medical Centre

Ananya Choudhury, MA, PhD, MRCP

The Christie NHS Foundation Trust

Vanita Noronha, MD

Tata Memorial Hospital

Regional Collaborator Committee

Daiming Fan, MD, PhD

Daping Hospital of Third Military Medical University
China Anti-Cancer Association

Jun Guo, MD, PhD

Peking University Cancer Hospital
Chinese Society of Clinical Oncology

Milita Zaheed, FRACP, MMed

Prince of Wales Hospital
Clinical Oncology Society of Australia

Molly SC Li, MBBS

The Chinese University of Hong Kong
Hong Kong Cancer Therapy Society

Sumant Gupta, DM

Sarvoday Hospital
Indian Society of Oncology

Koji Kono, MD, PhD

Fukushima Medical University
Japan Society of Clinical Oncology

Kan Yonemori, MD, PhD

National Cancer Center Hospital
Japanese Society of Medical Oncology

Young Saing Kim, MD

Gachon University Gil Medical Center
Korean Society of Medical Oncology

Jia (Jenny) Liu, MD, PhD

The Kinghorn Cancer Centre, St. Vincent's Hospital
Medical Oncology Group of Australia

Rachel Purcell, PhD, MSc

University of Otago
New Zealand Society of Oncology

Dennis Santos, MD

Mission Hospital, Philippines
Philippine Society of Medical Oncology

Jason Yongsheng Chan, MBBS, PhD

National Cancer Centre Singapore
Singapore Society of Oncology

Jen-Shi Chen, MD

Chang Gung Memorial Hospital
Taiwan Oncology Society

Naiyarat Prasongsook, MD, MS

Phramongkutklao Hospital
Thai Society of Clinical Oncology

Anh Tuan Pham, MD, PhD

Vietnam National Cancer Hospital
Vietnam Cancer Association

Regional Collaborators

ASCO

China Anti-Cancer Association

Chinese Society of Clinical Oncology

Clinical Oncology Society of Australia

Hong Kong Cancer Therapy Society

Indian Society of Oncology

Japan Society of Clinical Oncology

Japanese Society of Medical Oncology

Korean Society of Medical Oncology

Medical Oncology Group of Australia

New Zealand Society of Oncology

Philippine Society of Medical Oncology

Singapore Society of Oncology

Taiwan Oncology Society

Thai Society of Clinical Oncology

Vietnam Cancer Association

News Planning Team

Julie R. Gralow, MD, FACP, FASCO

ASCO Chief Medical Officer and Executive Vice President

Rebecca Alexandra Dent, MD, FASCO

National Cancer Centre Singapore

Julian C. Hong, MD, MS

University of California San Francisco

Michael Lowe, MD

Emory University

Rodrigo Munhoz, MD

Hospital Sírio-Libanês in São Paulo, Brazil

Vishwanath Sathyanarayanan, MD

Apollo Hospitals Bannerghatta Road, Bangalore

Rachna T. Shroff, MD, MS, FASCO

The University of Arizona Cancer Center

Conquer Cancer[®], the ASCO Foundation, Merit Award Recipients

Conquer Cancer, the ASCO Foundation, Merit Awards are designed to further promote quality clinical research by young scientists. A select number of Merit Awards are given annually to recognize outstanding research in abstracts submitted for presentation at the ASCO Breakthrough.

Shankar Biswas, MD, Sharda Hospital
Cho Han Chiang, MD, MSCI, Northwell Health Cancer Institute
Jen-Yu Chuang, MD, MacKay Memorial Hospital
Rahul Falodia, All India Institute of Medical Sciences
Cher Ying Foo, MD, Rochester General Hospital
Amanda Guo, PhD, Genome Institute of Singapore
Belinda Jiao, MD, McGill University
Prabhpreet Kaur, Yong Loo Lin School of Medicine, National University of Singapore
Yan Leyfman, MD, New York Presbyterian Hospital
Yiming Lv, MD, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Dang Nguyen, DM, DMSc, Medical Genetics Institute

Minh-Tri Phan, MD, University of Medicine and Pharmacy at Hue University
Suhana Sulfiker, MD, All India Institute of Medical Sciences
Dmitrii Shek, MD, PhD, Central Coast Cancer Centre, Gosford Hospital
Sara Tasnim, BPharm, MSc, Lee Kong Chian School of Medicine, Nanyang Technological University
Thi Tuong Vi Van, BSc, Medical Genetics Institute
Himanshu Varshney, MD, All India Institute of Medical Sciences
Poornima Verma, PhD, Sanjay Gandhi Postgraduate Institute of Medical Sciences
Pratibha Yadav, BSc, MSc, Christian Medical College
Chenghui Yang, PhD, The First Affiliated Hospital of Wenzhou Medical University

Abstract Award Recipients

ASCO is pleased to recognize the presenting authors of the 40 highest-rated abstracts selected for presentation at this year's meeting. These awards are supported by the Mission Endowment of Conquer Cancer, the ASCO Foundation.

Sarina Ailawadi, DO, University Hospitals, Case Western Reserve University
Pimsiri Aksornrung, BSN, BN, Bumrungrad International Hospital
Suboj Babykutty, PhD, Mar Ivanios College (Autonomous)
Haotian Cao, PhD, MB, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Tom Wei-Wu Chen, MD, PhD, Center of Excellence for Sarcoma, National Taiwan University Hospital
Viacheslav Chubenko, MD, PhD, Napalkov State Budgetary Healthcare Institution
Jayson L. Co, MD, MSc, University of Santo Tomas Hospital
Tammy Hshieh, MD, MPH, Dana-Farber Cancer Institute
Hanguang Hu, PhD, The Second Affiliated Hospital, Zhejiang University School of Medicine
Cheng Xu, MD, Sun Yat-sen University Cancer Center/Key Laboratory of Oncology in South China
Nur Diana Ishak, National Cancer Centre
Fuminori Ito, National Cancer Center Hospital East
Ze Jin, MD, DM, Icahn School of Medicine at Mount Sinai
Ning Kang, Sun Yat-sen University Cancer Center
Anita Kinney, PhD, RN, Rutgers Cancer Institute
Yeongkeun Kwon, MD, Korea University College of Medicine
Ho Cheung William Li, PhD, The Chinese University of Hong Kong
Jinjie Li, Tongji Hospital, Huazhong University of Science and Technology
Chengyang Luo, The First Affiliated Hospital of Zhengzhou University
Ruqayya Manzoor, FCPS, MBBS, Pakistan Institute of Medical Sciences
Yuta Maruki, MD, National Cancer Center Hospital

Anh Nguyen, Medical Genetics Institute
Ryosuke Okamura, MD, PhD, Kyoto University Graduate School of Medicine
Muhammad Hassan Ashraf Rai, Shifa College of Medicine, Shifa Tameer-e-Millat University
Evgeniya Ratova P. Hertsen, Moscow Oncology Research Institute, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Huei Ti Soh, South Western Sydney Local Health District
Venkatraman Radhakrishnan, MD, MBBS, MSc, DM, Cancer Institute (WIA)
Li-Yue Sun, MD, PhD, The First Affiliated Hospital of Jinan University
Huilai Zhang, Tianjin Medical University Cancer Institute and Hospital
Tira Jing Ying Tan, MBBS, National Cancer Centre Singapore
Laure-Anne Marie Nicole Teuwen, MD, PhD, Antwerp University Hospital
Le-Tho T. Vo, BSc, Medical Genetics Institute
Zhen Wang, MD, PhD, The Second Affiliated Hospital, Zhejiang University School of Medicine
Tingyu Wu, MD, PhD, Shanghai Colorectal Cancer Research Center, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Suwanna Rinchai, BSN, Bumrungrad International Hospital
Mengyuan Yang, National Cancer Centre
Chun Yang, School of Pharmacy, China Medical University
Yoon Sim Yap, PhD, MBBS, FRACP, National Cancer Centre Singapore
Chunbo Zhao, Harbin Medical University Cancer Hospital
Takumi Kozu, Kyoto University Graduate School of Medicine

Feedback and Certificates

We value your feedback! Please visit asco.org/bt-program or use the ASCO Meetings app to provide feedback about the sessions and the meeting.

Share Feedback on your Meeting Experience:



Continuing education credit and Maintenance of Certification points are not offered at this meeting. You can access a Certificate of Attendance at profile.asco.org.

Conflict of Interest Disclosure

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held

and compensated unless otherwise noted (I = Immediate family member; Inst = My Institution). Disclosures are submitted per the ASCO Policy for Relationships with Companies.

Attendee Resources

ASCO Customer Service

ASCO Customer Service, located in the Centre Atrium, will be available to assist you during the following times:

- Thursday: 07:45-17:45
- Friday: 07:45-18:00
- Saturday: 07:15-16:15

ASCO Meetings Mobile App

Download or update the ASCO Meetings mobile app to:

- Search sessions and presentation details;
- Create a customized agenda;
- Read abstracts;
- Pose questions to speakers during sessions; and
- Respond to presenter polls.

The ASCO Meetings app is available for both Apple and Android users via the app stores. The program is also available on asco.org/bt-program. Attendees must use their ASCO.org username to log in to some online resources. If you need help retrieving your username or updating your primary email address for validation, visit the ASCO Customer Service Desk in the Centre Atrium.

Scan the appropriate QR code below to access your device's app store:

Apple



Android



Asia-Pacific Community of Practice

The Asia-Pacific Community of Practice will host a roundtable discussion on Friday at 07:45 in the Enterprise Room. Community Champions will facilitate a conversation on existing and needed Asia-Pacific networks and programs. Light refreshments will be provided. This event is open to all, but seating is limited and available on a first-come, first-served basis.

Cultural Experiences With Local Artisans

ASCO has partnered with two local artisans to provide unique cultural experiences for our attendees. Visit the artisans in the Fairmont Ballroom Foyer to experience the following activities.

On Thursday, from 12:00-13:30, participate in a hands-on demonstration of Ketupat Weaving. Attendees will use colorful ribbon to create a decorative diamond-shaped pouch resembling traditional Malaysian ketupat rice cakes.

On Friday, from 12:15-13:45, watch a local batik artisan at work. The artist will be hand-painting a piece of batik, an ancient textile art utilizing wax resist and dye to create intricate patterns on fabric. Batik pieces will be available for purchase.

Exhibits

Attendees are encouraged to visit the exhibits in the Fairmont Ballroom Foyer on June 25 from 07:45-17:00 and June 26 from 07:45-18:00. The exhibits offer an opportunity to extend your learning about the most advanced therapies, products, and services in cancer care. Visit breakthrough.asco.org to view a list of exhibiting companies.

Meeting Videos, Slides, and Posters

On-demand versions of meeting videos (recordings of the sessions) and slides (downloadable slide decks) will be available to all attendees within hours following each session. Posters will be available to all attendees on the morning of the presentation. To view these materials, visit the ASCO Meetings mobile app or visit asco.org/bt-program.

Onsite Connections

Expand your network by participating in programming designed to help you connect with other attendees and expert faculty during the meeting. Connection opportunities include expert roundtable discussions, trainee and early-career networking, a Women at ASCO Breakthrough meet and greet (open to all), and guided poster walks. More information on these events can be found at breakthrough.asco.org. All networking events are in-person only. Space is limited and available on a first-come, first-served basis.

Policies

Important policies for this Symposium, including the Attendee Code of Conduct, are available at breakthrough.asco.org.

Poster, Coat, and Bag Check

Complimentary poster, coat, and bag check is available at Registration in the Centre Atrium. Items may not be left overnight. All unclaimed items at the end of the meeting will be turned over to the Raffles City Convention Centre.

Supplies and Device Charging

Note pads and pens will be available in the General Session Room. Power strips for charging your devices are located throughout the General Session Room.

Wi-Fi

Using personal Wi-Fi (hot spot) devices can negatively impact the attendee Wi-Fi experience. For the best experience for all attendees, please refrain from using your personal Wi-Fi device.

ASCO and Conquer Cancer, the ASCO Foundation, would like to thank the following sponsorship donors of ASCO Breakthrough: AstraZeneca; BeOne; GSK; Johnson & Johnson; Lilly; Moderna; MSD; and Revolution Medicines.

Program at a Glance

Thursday, June 25

All times in SGT.

07:45-17:00	Exhibits Open
07:45-08:30	Complimentary Light Morning Refreshments and Poster Hanging Time
08:30-09:30	Keynote
09:50-11:05	Young and Diagnosed: Confronting the Global Surge of Early-Onset Cancers
11:25-12:10	Clinical Solutions: Challenging Cases in Liver Cancer
12:10-13:30	Poster Session A: Artificial Intelligence/Digital Technology, Central Nervous System Tumors, Gastrointestinal Cancers, Melanoma/Skin Cancers, Other Malignancies or Topics, Sarcoma <i>With complimentary lunch</i>
12:10-13:30	Trials in Progress Poster Session A: Gastrointestinal Cancers <i>With complimentary lunch</i>
12:30-13:15	Disease-Focused Networking Luncheon* <i>With complimentary lunch</i>
12:30-13:15	Guided Poster Walks*
13:30-15:00	Oral Abstract Session A: Clinical Trials in Early Breast and Colorectal Cancer—Targeted and Immunoradiotherapy Strategies
15:20-16:35	Antibody-Drug Conjugates: Breaking Boundaries in Cancer Care
16:50-17:50	Recent Updates in Hematologic Malignancies

*Space is limited and is available on a first-come, first-served basis.

Program at a Glance

Friday, June 26

07:45-18:00	Exhibits Open
07:45-08:30	Complimentary Light Morning Refreshments and Poster Hanging Time
07:45-08:30	Asia-Pacific Community of Practice Roundtable Discussion
08:30-09:45	What Does It Take to Make Clinical Artificial Intelligence a Reality at the Bedside? A Discussion
10:05-11:20	Minimal Residual Disease in 2026: What the Evidence Supports and What Is on the Horizon
11:40-12:25	Clinical Solutions: Challenging Cases in Cervical Cancer
12:25-13:40	Poster Session B: Genitourinary Cancers, Hematologic Malignancies, Lung Cancer, Quality of Care <i>With complimentary lunch</i>
12:25-13:40	Trials in Progress Poster Session B: Genitourinary Cancers, Lung Cancer <i>With complimentary lunch</i>
12:45-13:30	Guided Poster Walks*
12:45-13:30	Trainee and Early-Career Networking Luncheon* <i>With complimentary lunch</i>
13:40-15:10	Oral Abstract Session B: Cancer Detection and Precision Medicine
15:30-16:45	From Data to Delivery: Advancing Equitable Oncology in the Asia-Pacific Region—Bridging Gaps With Common Sense
17:00-18:00	Recent Updates in Genitourinary Cancers (Prostate/Bladder)

*Space is limited and is available on a first-come, first-served basis.

Program at a Glance

Saturday, June 27

07:30-08:30	Complimentary Light Morning Refreshments and Poster Hanging Time
07:30-08:15	Women at ASCO Breakthrough: Meet and Greet (Open to All)*
08:30-09:30	Keynote
09:50-11:05	Stronger Together: New Immunotherapy Combination Strategies
11:25-12:10	Clinical Solutions: Challenging Cases in Oral Cavity Cancer
12:10-13:30	Poster Session C: Breast Cancer, Developmental Therapeutics, Genetics/Genomics/Multiomics, Gynecologic Cancer, Head and Neck Cancer <i>With complimentary lunch</i>
12:10-13:30	Trials in Progress Poster Session C: Breast Cancer, Developmental Therapeutics, Head and Neck Cancer <i>With complimentary lunch</i>
12:30-13:15	Guided Poster Walks*
13:30-15:00	Oral Abstract Session C: Quality of Care and Palliative and Supportive Care
15:20-16:20	Recent Updates in Lung Cancer

*Space is limited and is available on a first-come, first-served basis.

Thursday, June 25

07:45-17:00

Exhibits Open

Level 4, Fairmont Ballroom Foyer

07:45-08:30

Light Morning Refreshments

Level 4, Fairmont Ballroom Foyer

08:30-09:30

Keynote

Level 4, Padang Ballroom

Welcome of the Day

Yun Yen, MD, PhD, FACP, FASCO

Taipei Medical University

Welcome From the Singapore Society of Oncology

Eileen Yi Ling Poon, MD

National Cancer Centre Singapore

Chair and Keynote Introduction

Roselle B. De Guzman, MD, FASCO—Chair

Manila Central University

Precision Public Health: Optimizing Cancer Screening via Risk Stratification

Nora Pashayan, MD, PhD

University of Cambridge

Panel Question and Answer

09:50-11:05

Young and Diagnosed: Confronting the Global Surge of Early-Onset Cancers

Level 4, Padang Ballroom

Kimmie Ng, MD, MPH, FASCO—Chair

Dana-Farber Cancer Institute

Jeong Eun Kim, MD, PhD—Chair

Asan Medical Center

Living Young With Cancer: The Patient Voice

Poonam Bagai

CanKids KidsCan

Global Epidemiology and Genetic Underpinnings of Early-Onset Cancer

Tomotaka Ugai, MD, PhD

Harvard Medical School

Exploring Molecular Underpinnings of Early-Onset Cancer

Paul Brennan, PhD

International Agency for Research on Cancer

Clinical Management of Early-Onset Cancer

Herbert H. Loong, MBBS, FRCP, FASCO

The Chinese University of Hong Kong

Panel Question and Answer

11:25-12:10

Clinical Solutions: Challenging Cases in Liver Cancer

Level 4, Padang Ballroom

Dawn Q. Chong, MPH, MBBS, MRCP—Chair

National Cancer Centre Singapore

Medical Oncology Perspective: Recent Advances in Liver Cancer

David Tai, MBBS

National Cancer Centre Singapore

Medical Oncology Perspective: Navigating Optimal Treatment

Naiyarat Prasongsook, MD, MS

Phramongkutklao Hospital and College of Medicine

Panel Question and Answer

12:10-13:30

Poster Session A: Artificial Intelligence/Digital Technology, Central Nervous System Tumors, Gastrointestinal Cancers, Melanoma/Skin Cancers, Other Malignancies or Topics, Sarcoma

Level 4, Canning Ballroom

With complimentary lunch. See p. 18 for a full listing of posters.

12:10-13:30

Trials in Progress Poster Session A: Gastrointestinal Cancers

Level 4, Canning Ballroom

With complimentary lunch. See p. 23 for a full listing of posters.

12:30-13:15

Guided Poster Walks

Level 4, Canning Ballroom

Meet at the Poster Assistance Desk to participate. See p. 18 for a full listing of posters.

Artificial Intelligence

Joe Yeong, PhD, MBBS—Poster Walk Leader

Institute of Molecular and Cell Biology, Agency for Science, Technology and Research

Gastrointestinal Cancers

Joon Oh Park, MD, PhD—Poster Walk Leader

Samsung Medical Center, Sungkyunkwan University

12:30-13:15

Disease-Focused Networking Luncheon

Level 4, Enterprise Room

With complimentary lunch.

13:30-15:00

Oral Abstract Session A: Clinical Trials in Early Breast and Colorectal Cancer—Targeted and Immunoradiotherapy Strategies

Level 4, Padang Ballroom

Martin R. Stockler, MBBS, MS—Chair

The University of Sydney

Rebecca Alexandra Dent, MD, FASCO—Chair

National Cancer Centre Singapore and Duke-NUS Medical School

Abstract 27: Inetetamab combined with pyrotinib for neoadjuvant treatment of HER2-positive locally advanced breast cancer (neoPICD): A prospective, multicenter, single-arm phase II trial.

First Author: Chenghui Yang, PhD

Abstract 28: INAVO120 phase 3 trial: Subgroup analyses of Asian patients (pts) with *PIK3CA*-mutated (mut), hormone receptor-positive, HER2-negative (HER2-), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).

First Author: Yoon Sim Yap, PhD, MBBS, FRACP

Discussion: Clinton Yam, MD

The University of Texas MD Anderson Cancer Center

Abstract 92: Short-course radiotherapy and chemotherapy with or without PD-L1 blockade (envafolimab) for MSS locally advanced rectal cancer: Interim analysis of the randomized phase III PRECAM-R trial.

First Author: Yiming Lv, MD

Abstract 93: Long-term neoadjuvant chemoradiotherapy combined with camrelizumab for locally advanced rectal cancer: A single-arm, prospective, phase II clinical study.

First Author: Chunbo Zhao

Discussion: Gwo Fuang Ho, MBChB
University Malaya Medical Centre

Panel Question and Answer

15:20-16:35

Antibody-Drug Conjugates: Breaking Boundaries in Cancer Care
Level 4, Padang Ballroom

David Dai-Wee Lee, MBBS—Chair
Sunway Medical Centre

Jun Ma, MD—Chair
Sun Yat-sen University Cancer Center

Antibody-Drug Conjugates in Lung Cancer

David R. Gandara, MD, FASCO
University of California Davis Comprehensive Cancer Center

Antibody-Drug Conjugates in Breast Cancer

Naoto Tada Ueno, MD, PhD
University of Hawai'i Cancer Center

Development of Antibody-Drug Conjugates in China

Zhu Yi, PhD
Fudan University, Sichuan Biokin Pharmaceutical

The Global Antibody-Drug Conjugate Ecosystem

Lillian L. Siu, MD, FRCPC, FASCO
Princess Margaret Cancer Centre

Panel Question and Answer

16:50-17:50

Recent Updates in Hematologic Malignancies
Level 4, Padang Ballroom

Eileen Yi Ling Poon, MD—Chair
National Cancer Centre Singapore

Recent Updates in Hematologic Malignancies

Francesca L. Lim, MBBS
Singapore General Hospital

Recent Updates in Hematologic Malignancies: Considerations in Asia-Pacific Region

Bor-Sheng Ko, MD, PhD
National Taiwan University Cancer Center

Panel Question and Answer

Friday, June 26

07:45-18:00

Exhibits Open

Level 4, Fairmont Ballroom Foyer

07:45-08:30

Light Morning Refreshments

Level 4, Fairmont Ballroom Foyer

08:30-09:45

What Does It Take to Make Clinical Artificial Intelligence a Reality at the Bedside? A Discussion

Level 4, Padang Ballroom

Welcome From the ASCO President

Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO
Beth Israel Deaconess Medical Center, Harvard Medical School

Welcome and Session Introduction

Melvin L.K. Chua, PhD, MBBS, FRCR, FASCO—Chair
National Cancer Centre Singapore

David Goldstein, MD, MBBS—Chair
Prince of Wales Hospital, University of New South Wales

Artificial Intelligence Tools for Clinical Care in Low- and Middle-Income Countries

Naveen Nagar, MBBS, MHA
Apollo Hospitals

Artificial Intelligence for Diagnostic Imaging

Daniel Truhn, MD, MSc
University Hospital Aachen

Agentic Artificial Intelligence and Tumor Boards

Arsela Prelaj, MD, PhD
Fondazione IRCCS Istituto Nazionale dei Tumori

Artificial Intelligence to Bridge Global Clinical Trials Gap

Huren Sivaraj, MRCP, MBBS
Oncoshot Pte. Ltd.

Panel Question and Answer

10:05-11:20

Minimal Residual Disease in 2026: What the Evidence Supports and What Is on the Horizon

Level 4, Padang Ballroom

Natasha B. Leigh, MD, FASCO—Chair
Princess Margaret Cancer Centre

Sue S. Yom, MD, PhD, FASTRO, FACR—Chair
UCSF Medical Center at Mount Zion

Minimal Residual Disease Updates in Colon Cancer

Takayuki Yoshino, MD, PhD
National Cancer Center Hospital East

Minimal Residual Disease Updates in Breast Cancer

Hiroji Iwata, MD
Nagoya City University

Minimal Residual Disease Updates in Lung Cancer

Tony S.K. Mok, MD, FRCPC, FASCO
The Chinese University of Hong Kong

Clinical Trials to Demonstrate Utility

Jeanne Tie, MD, FRACP, MBChB
Peter MacCallum Cancer Centre

Panel Question and Answer

11:40-12:25

Clinical Solutions: Challenging Cases in Cervical Cancer

Level 4, Padang Ballroom

Sonia Mathai, MD, MPH—Chair
Tata Medical Center

Radiation Oncology Perspective: Recent Advances in the Field

Pittaya Dankulchai, MD
Siriraj Hospital

Radiation Oncology Perspective: Practical Challenges in Low-Resource Settings

Abhishek Shankar, MD, MBA
All India Institute of Medical Sciences

Panel Question and Answer

12:25-13:40

Poster Session B: Genitourinary Cancers, Hematologic Malignancies, Lung Cancer, Quality of Care

Level 4, Canning Ballroom
With complimentary lunch. See p. 24 for a full listing of posters.

12:25-13:40

Trials in Progress Poster Session B: Genitourinary Cancers, Lung Cancer

Level 4, Canning Ballroom
With complimentary lunch. See p. 29 for a full listing of posters.

12:45-13:30

Guided Poster Walks

Level 4, Canning Ballroom
Meet at the Poster Assistance Desk to participate. See p. 24 for a full listing of posters.

Lung Cancer

Vanita Noronha, MD—Poster Walk Leader
Tata Memorial Hospital

Genitourinary Cancers

Ravindran Kanesvaran, MD—Poster Walk Leader
National Cancer Centre Singapore

Quality of Care and Palliative Care

Monica Malik, MD, DNB, FASCO—Poster Walk Leader
Nizam's Institute of Medical Sciences

12:45-13:30

Trainee and Early-Career Networking Luncheon

Level 4, Enterprise Room
With complimentary lunch.

13:40-15:10

Oral Abstract Session B: Cancer Detection and Precision Medicine

Level 4, Padang Ballroom

Milila Zaheed, FRACP, MMed—Chair
Prince of Wales Hospital

Joe Yeong, PhD, MBBS—Chair
Institute of Molecular and Cell Biology, Agency for Science,
Technology and Research

Abstract 201: Pivotal PYNACLE phase 2 trial of rezatapopt in heavily pre-treated, advanced solid tumors with a TP53 Y220C mutation: Initial ovarian cancer analysis.

First Author: Tira Jing Ying Tan, MBBS

Abstract 202: Molecular residual disease detection for ovarian cancer using a WGS-based ctDNA assay: Initial findings from the MONSTAR-SCREEN-3.

First Author: Fuminori Ito

Discussion: Natalie Ngoi, MD
National University Cancer Institute, Singapore

Abstract 94: Development of a multidimensional diagnostic model integrating cfDNA methylation and clinical parameters for colorectal cancer and precancerous lesions using artificial intelligence.

First Author: Li-Yue Sun, MD, PhD

Abstract 95: Integrated fragmentomics and droplet digital PCR-based methylation analysis of cell-free DNA for enhanced detection of precancerous lesions and early colorectal cancer.

First Author: Thi Tuong Vi Van, BSc

Discussion: Desmond Yip, MBBS, FRACP
Canberra Hospital

Panel Question and Answer

15:30-16:45

From Data to Delivery: Advancing Equitable Oncology in the Asia-Pacific Region—Bridging Gaps With Common Sense

Level 4, Padang Ballroom

Roselle B. De Guzman, MD, FASCO—Chair
Manila Central University

Annie N. M. Wong, PhD, FRACP, MBChB—Chair
Peter MacCallum Cancer Centre

Scope and Drivers of Cancer Health Disparities Across India and South Asia

C. S. Pramesh, MBBS, MS, FRCS
Tata Memorial Hospital

Cancer Health Disparities Amongst Native Hawaiian and Pacific Islander Populations

Neal Palafox, MD, MPH
University of Hawai'i Cancer Center

Building a Unified Platform for Clinical Trials in Asia: Advancing Regional Collaboration and Global Impact

Kan Yonemori, MD, PhD
National Cancer Center Hospital

Meeting the Challenges With Common Sense

Bishal Gyawali, MD, PhD, FASCO
Queen's University

Panel Question and Answer

17:00-18:00

Recent Updates in Genitourinary Cancers (Prostate/Bladder)
Level 4, Padang Ballroom

Ravindran Kanesvaran, MD—Chair
National Cancer Centre Singapore

Recent Updates in Genitourinary Cancers (Prostate/Bladder)

Primo N. Lara Jr, MD, FASCO
University of California Davis Comprehensive Cancer Center

Recent Updates in Genitourinary Cancers (Prostate/Bladder): Considerations in the Asia-Pacific Region

Shankar Siva, PhD
Peter MacCallum Cancer Centre

Panel Question and Answer

Saturday, June 27

07:30-08:30

Light Morning Refreshments

Level 4, Fairmont Ballroom Foyer

07:30-08:15

Women at ASCO Breakthrough: Meet and Greet (Open to All)

Level 4, Fairmont Ballroom Foyer

08:30-09:30

Keynote

Level 4, Padang Ballroom

Welcome of the Day

Roselle B. De Guzman, MD, FASCO

Manila Central University

Keynote Introduction

Melvin L.K. Chua, PhD, MBBS, FRCR, FASCO—Chair

National Cancer Centre Singapore

An Update on the Emerging Field of Cell-Free DNA Fragmentomics in Liquid Biopsy

Yuk Ming Dennis Lo, MD, PhD

The Chinese University of Hong Kong

Panel Question and Answer

09:50-11:05

Stronger Together: New Immunotherapy Combination Strategies

Level 4, Padang Ballroom

Ananya Choudhury, PhD, MA, MRCP, FRCR—Chair

The Christie NHS Foundation Trust

Hironobu Minami, MD, DMSc—Chair

Kobe University Graduate School of Medicine

Low Dose, High Impact

Wan Zamariah Wan Ishak, MD, MBBS

University of Malaya Medical Centre

Is There Any Synergy Between Molecular Radiotherapy and Checkpoint Inhibitors?

Nuradh Joseph, MD, MBBS, MRCP, FRCR

Ministry of Health Sri Lanka

The Two Sides of Combinatorial Immunotherapy Strategies: Enhanced Efficacy Versus Managing Toxicities

Daniel Shao-Weng Tan, PhD, MBBS, BSc, MRCP

National Cancer Centre Singapore

The Right Patient, The Right Time: Leveraging Biomarkers to Personalize Immunotherapy

Elizabeth Steinberg, PhD

Genentech, Inc.

Panel Question and Answer

11:25-12:10

Clinical Solutions: Challenging Cases in Oral Cavity Cancer

Level 4, Padang Ballroom

Sue S. Yom, MD, PhD, FASTRO, FACR—Chair

University of California San Francisco

Surgeon Perspective

N. Gopalakrishna Iyer, PhD, MBBS

National Cancer Centre Singapore

Medical Oncology and Clinical Trialist Perspective

Kumar Prabhash, MD

Tata Memorial Hospital

Panel Question and Answer

12:10-13:30

Poster Session C: Breast Cancer, Developmental Therapeutics, Genetics/Genomics/Multiomics, Gynecologic Cancer, Head and Neck Cancer

Level 4, Canning Ballroom

With complimentary lunch. See p. 30 for a full listing of posters.

12:10-13:30

Trials in Progress Poster Session C: Breast Cancer, Developmental Therapeutics, Head and Neck Cancer

Level 4, Canning Ballroom

With complimentary lunch. See p. 35 for a full listing of posters.

12:30-13:15

Guided Poster Walks

Level 4, Canning Ballroom

Meet at the Poster Assistance Desk to participate. See p. 30 for a full listing of posters.

Developmental Therapeutics

Sophia Wong, MBBS—Poster Walk Leader

National Cancer Centre Singapore

Breast Cancer

Clinton Yam, MD—Poster Walk Leader

The University of Texas MD Anderson Cancer Center

13:30-15:00

Oral Abstract Session C: Quality of Care and Palliative and Supportive Care

Level 4, Padang Ballroom

Monica Malik, MD, DNB, FASCO—Chair

Nizam's Institute of Medical Sciences

Nisha Shariff, MBBS—Chair

University Malaya Medical Center

Abstract 96: The intersection between frailty and unmet health-related social needs: Establishing the complex frailty paradigm.

First Author: Tammy Hshieh

Abstract 29: Early best supportive care and quality of life trajectories in breast cancer: A multivariate analysis of treatment response patterns.

First Author: Himanshu Varshney, MD

Discussion: Nisha Shariff, MBBS

University Malaya Medical Center

Abstract 314: Effects of a self-determination theory-based smoking cessation intervention plus instant messaging via instant messaging for smokers with cancer: A randomized controlled trial.

First Author: Ho Cheung William Li, PhD

Abstract 313: Efficacy of prophylactic dexamethasone in preventing opioid-induced nausea and vomiting in cancer patients: A randomized controlled trial.

First Author: Suhana Sulfikar Sr, MD

Discussion: Lawson Eng, MD, FRCPC, SM
Princess Margaret Cancer Centre, University Health Network

Panel Question and Answer

15:20-16:20

Recent Updates in Lung Cancer

Level 4, Padang Ballroom

Kevin Lee Min Chua, MBBS, FRCR—Chair
National Cancer Centre Singapore

Recent Updates in Lung Cancer

Navneet Singh, MD, DM, FRCP, FASCO
Postgraduate Institute of Medical Education and Research

Recent Updates in Lung Cancer: Considerations in the Asia-Pacific Region

Molly SC Li, MBBS
The Chinese University of Hong Kong

Panel Question and Answer

Closing Remarks

Roselle B. De Guzman, MD, FASCO
Manila Central University

Poster Sessions

Thursday, June 25

12:10-13:30

Poster Session A: Artificial Intelligence/Digital Technology, Central Nervous System Tumors, Gastrointestinal Cancers, Melanoma/Skin Cancers, Other Malignancies or Topics, Sarcoma
Level 4, Canning Ballroom

Posters by Topic

Artificial Intelligence/Digital Technology

- Advanced Disease: A1
- Diagnostics: A2
- Early Detection and Surveillance: A3, A4
- Models of Care and Care Delivery: A5-A7
- Omics for Precision Medicine: A8-A12
- Prevention and Screening: B1
- Real-World Evidence/Real-World Data: B2-B4
- Technology and Innovations: B5-B8, C1-C4
- Translational Research: C5
- Tumor Biology, Biomarkers, and Pathology: C6

Central Nervous System Tumors

- Immunotherapies: C7-C9
- Symptoms, Toxicities, and Whole-Person Care: C10
- Translational Research: C11
- Tumor Biology, Biomarkers, and Pathology: C12
- Other Therapeutic Intervention: D1, D2

Gastrointestinal Cancer

- Advanced Disease: D3- D6
- Diagnostics: D7, D8
- Early Detection and Surveillance: D9, D10
- Immunotherapies: D11-D16, E1-E3
- Local Disease: E4
- Models of Care and Care Delivery: E5-E6
- Multimodality Treatments: E8, E9
- Prevention and Screening: E10
- Real-World Evidence/Real-World Data: E11-E20, F1-F10
- Targeted Therapies: F11
- Technology and Innovations: F12
- Translational Research: F13-F17
- Tumor Biology, Biomarkers, and Pathology: F18-F20, G1-G3
- Other Therapeutic Intervention: G5-G7

Melanoma/Skin Cancers

- Targeted Therapies: G8

Other Malignancies or Topics

- Advanced Disease: G9
- Immunotherapies: G10, G11
- Omics for Precision Medicine: G12
- Prevention and Screening: G13
- Real-World Evidence/Real-World Data: G15-G17
- Symptoms, Toxicities, and Whole-Person Care: G18-G20
- Targeted Therapies: H1
- Translational Research: H2, H3
- Tumor Biology, Biomarkers, and Pathology: H4
- Other Therapeutic Intervention: H5, H6

Sarcoma

- Real-World Evidence/Real-World Data: H7

Board A1 Abstract 1: Causal machine learning–guided personalized immunochemotherapy strategies in intrahepatic cholangiocarcinoma (CMICC).
First Author: Jun-Hao Mei

Board A2 Abstract 2: Artificial intelligence–assisted colonoscopy and adenoma detection: An updated systematic review and meta-analysis of 42 studies.
First Author: Shabih Raza Farista, MBBS

Board A3 Abstract 3: Closing the diagnostic gap: A three-step AI safety-net workflow to capture missed lung nodules on chest radiographs in routine clinical practice.
First Author: Passakorn Wanchaijiraboon, MD

Board A4 Abstract 4: AI-assisted colonoscopy and detection/miss of adenomas and sessile serrated lesions: An updated systematic review and meta-analysis.
First Author: Mazhar Ali, MBBS

Board A5 Abstract 5: AI as a clinical teaching co-pilot: A real-world evaluation of an LLM-integrated bedside microteaching model in inpatient oncology.
First Author: Mathew George, MD

Board A6 Abstract 6: Patient preference for large language model (LLM)–optimised oncology trial information: A randomised controlled crossover study.
First Author: Minh Tran, PhD

Board A7 Abstract 7: The University of New Mexico hepatobiliary ECHO: A scalable model for multidisciplinary cancer care.
First Author: Lynn Saavedra, RN, MSN, OCN, MS

Board A8 Abstract 8: Flux-coupled network pharmacology to identify AR–HIF1A–mTOR tri-axis as a mechanistic vulnerability in genitourinary (GU) cancers.
First Author: Lutfat Abimbola Usman, PhD, MSc

Board A9 Abstract 9: Bayesian multimodal modeling with explainable artificial intelligence to predict response to GBE1-targeted metabolic therapy in colorectal cancer.
First Author: Fang-Chi Hsu, PhD

Board A10 Abstract 10: Transformer-based multi-omics synthesis for early risk stratification and preventive surveillance in liver oncology.
First Author: Umesh Gangadhar, MBA, BM, HCS

Board A11 Abstract 11: An integrative multi-omics machine learning framework for precision metastasis prediction and clinical staging in non-small cell lung cancer.
First Author: Jinbin Wang, BSc

Board A12 Abstract 12: AI-driven oncogenic risk stratification in pediatric autism spectrum disorder: A multi-omic machine learning framework for early cancer prevention.
First Author: Anita Gangadhar

Board B1 Abstract 13: AI-driven mortality analysis of three major neoplasms in Mexico.
First Author: Miguel Patiño, MD, DM

Board B2 Abstract 14: Real-world performance of a multimodal cell-free DNA multi-cancer early detection test in Asian populations.
First Author: Dang Luu Hong Nguyen, DM, DMSc

- Board B3** **Abstract 15: Automated cancer data extraction using large language models: A scalable workflow for clinical documentation processing.**
First Author: See Boon Tay
- Board B4** **Abstract 16: Analytical validation of a 90-gene expression assay for pan-cancer tissue-of-origin classification in Southeast Asia.**
First Author: Zhe Sing Sin
- Board B5** **Abstract 17: From neuroscience to oncology: Multi-agent AI replicating neural reasoning architecture for evidence-based colon cancer clinical decisions.**
First Author: Noemi Perez Paz, PhD, MS
- Board B6** **Abstract 18: Expanding global access to oncology trials: mCODE-aligned AI for inclusive patient matching across literacy and resource settings.**
First Author: Yan Leyfman, MD
- Board B7** **Abstract 19: Disease-specific safety risks in oncology large language models: A multi-axis evaluation across solid tumor subtypes.**
First Author: Yan Leyfman, MD
- Board B8** **Abstract 20: Simulating expert oncologist-to-oncologist thinking and behavior: Multi-agent AI for precision oncology collaboration.**
First Author: Deva Datta Reddy Jyothi
- Board C1** **Abstract 21: A comparative analysis of frontier large language model (LLM) performance on standardized knowledge assessments and real world scenarios in genitourinary (GU) malignancies.**
First Author: Sameer S. Deshmukh, MD, MBBS
- Board C2** **Abstract 22: Semantic interpretation of prior therapy eligibility in oncology protocols: A comparative analysis of proprietary and open-source large language models (LLMs).**
First Author: Minh Tran, PhD
- Board C3** **Abstract 23: Automated tumor content analysis from whole slide images using deep learning models for NGS quality control in precision oncology.**
First Author: Satya Prakash Khuntia
- Board C4** **Abstract 24: Development and temporal validation of a machine learning–based cancer-specific early warning score for predicting clinical deterioration in oncology ICU patients.**
First Author: Shankar Biswas, MD
- Board C5** **Abstract 25: Multimodal spatiotemporal atlas to reveal CCDC3⁺ CAFs as drivers of liver metastasis in colorectal cancer.**
First Author: Weiping Zhu
- Board C6** **Abstract 26: Automation of OncoKB annotation to enhance efficiency and consistency of molecular tumor board workflows.**
First Author: Zit Liang Chan
- Board C7** **Abstract 69: B7H3/IL13Ra2 bispecific armored CAR-T for recurrent/refractory glioblastoma: Safety, efficacy, and immune dynamics.**
First Author: Shuyu Zheng, MD
- Board C8** **Abstract 70: Multi-mechanism armored B7H3/IL13Ra2 bispecific CAR-T for treatment of glioblastoma.**
First Author: Keming Zhang, MD, MSc
- Board C9** **Abstract 71: BC008-1A (PD-1/TIGIT bispecific antibody) in recurrent CNS WHO grade 4 glioma: Results from a randomized phase I study.**
First Author: Di Wang, MD
- Board C10** **Abstract 72: The impact of vertebral body irradiation techniques on dose distribution to cardiac substructure during craniospinal irradiation for pediatric medulloblastoma: A detailed dosimetric study.**
First Author: Huanzi Jiang, BCh
- Board C11** **Abstract 73: The prognostic significance of MYBL1 and MYBL2 genes in low-grade glioma.**
First Author: Abdallah Al-Ramadi
- Board C12** **Abstract 74: Unraveling the role of NLRP1-mediated inflammation in glioblastoma pathophysiology.**
First Author: Shalini Chhipa, MSc
- Board D1** **Abstract 75: Active bone marrow–sparing IMRT guided by SPECT/CT functional imaging to reduce hematologic toxicity in pediatric pelvic/craniospinal irradiation: A randomized controlled trial.**
First Author: Li Zhang
- Board D2** **Abstract 76: Engineered Escherichia coli Nissle 1917 carrying D-lactate dehydrogenase to suppress glioblastoma malignancy via gut-brain axis reprogramming.**
First Author: Anjing Chen, PhD
- Board D3** **Abstract 97: Efficacy and safety of first-line modified docetaxel, cisplatin, and fluorouracil (mDCF) in advanced esophageal cancer: A retrospective study from Viet Nam.**
First Author: Hong Thi Anh Can, MD
- Board D4** **Abstract 98: Hepatic arterial infusion chemotherapy combined with camrelizumab and lenvatinib in the treatment of advanced hepatocellular carcinoma: A retrospective study.**
First Author: Wei Dong
- Board D5** **Abstract 99: Real-world efficacy and survival outcomes of novel targeted therapies in advanced hepatocellular carcinoma from low- and middle-income countries.**
First Author: Aleena Nazar, MBBS
- Board D6** **Abstract 100: Liposomal irinotecan (HR070803) plus fluorouracil and bevacizumab as second-line treatment in advanced colorectal cancer: Cohort A results from a phase 2 trial.**
First Author: Hanguang Hu, PhD
- Board D7** **Abstract 101: ⁶⁸Ga-NODAGA-SNA009: A first-in-class single-domain antibody probe for rapid PET imaging of GPA33 in colorectal cancer.**
First Author: Zhao Yang
- Board D8** **Abstract 102: Addressing radiologist inter-reader variability in gastric cancer T staging: A prospective study using the dual-module AI model, TRACE.**
First Author: Chun Yang, BC

- Board D9** **Abstract 103: Circulating tumor suppressor microRNAs as minimally invasive biomarkers for early detection of colorectal cancer.**
First Author: Samiah Shahid
- Board D10** **Abstract 104: Endoscopic submucosal dissection for early gastrointestinal neoplasms: A prospective study of 50 cases in 45 patients in Vietnam.**
First Author: Duc Van Pham
- Board D11** **Abstract 105: ReIB/ILF2–GM-CSF loop to sustain MDSC-mediated prostate cancer immunosuppression.**
First Author: Yanyan Zhang
- Board D12** **Abstract 106: Neoadjuvant anti-PD-1 monotherapy in MSI-H locally advanced gastric cancer: 3-Year survival without surgery.**
First Author: Viacheslav Chubenko, MD, PhD
- Board D13** **Abstract 107: Adebrelimab plus interventional and targeted therapy for unresectable hepatocellular carcinoma: A single-arm, real-world study.**
First Author: Chenchen Zhao
- Board D14** **Abstract 108: Hepatic arterial infusion chemotherapy plus immune checkpoint inhibitors and lenvatinib for locally advanced biliary tract cancer: A single-arm, exploratory study.**
First Author: Tianci Wang
- Board D15** **Abstract 109: Pathological complete response after neoadjuvant chemoimmunotherapy with toripalimab or camrelizumab in esophageal squamous cell carcinoma: A systematic review and meta-analysis.**
First Author: Dimetrius Kukuh Prasajo Triaswhoro, MD
- Board D16** **Abstract 110: Neoadjuvant chemotherapy plus serplulimab and immuno-response molecular subtype for pMMR locally advanced rectal cancer (FIRM).**
First Author: Tingyu Wu, MD, PhD
- Board E1** **Abstract 111: A GAN-based multimodal framework for preoperative response prediction in HER2-negative locally advanced gastric cancer treated with neoadjuvant chemoimmunotherapy.**
First Author: Jia Wei
- Board E2** **Abstract 112: Nodal status–guided postoperative radiotherapy after neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter cohort study.**
First Author: Jinjie Li, BMedSci, MBBS
- Board E3** **Abstract 113: Efficacy and safety of first-line PD-1/PD-L1 inhibitor–based therapy in esophageal squamous cell carcinoma: A systematic review and meta-analysis.**
First Author: Mannal Ahmed, MBBS
- Board E4** **Abstract 114: Surgical outcomes and recurrence risk factors for rectal gastrointestinal stromal tumors: A comparison of transabdominal and transanal resection.**
First Author: Ran Xiong
- Board E5** **Abstract 115: Germline testing in pancreatic adenocarcinoma: A retrospective cohort study of germline genetic testing uptake, patterns of referral, clinical findings and impact in the South Western Sydney Local Health District.**
First Author: Huei Ti Soh
- Board E6** **Abstract 116: The PAN-SUR(IN) score for advanced pancreatic cancer: A comprehensive analysis of methodology, prognostic derivation, and clinical risk stratification.**
First Author: Chalermchai Lertanansit
- Board E8** **Abstract 118: Potential overtreatment in MRI-defined low-risk locally advanced rectal cancer in the era of neoadjuvant therapy: An international cohort study.**
First Author: Ryosuke Okamura, MD, PhD
- Board E9** **Abstract 119: Real-world outcomes of first-line palliative treatments in advanced biliary tract cancer: A single-center experience from Thailand.**
First Author: Teerarat Trakulphat, MS
- Board E10** **Abstract 120: Baseline COPD, mean lung dose, and longitudinal exhaled nitric oxide for predicting symptomatic radiation pneumonitis in esophageal squamous cell carcinoma: A prospective single-center pilot study.**
First Author: Mei Huang
- Board E11** **Abstract 121: Role of surgery in locally progressive gastrointestinal stromal tumors after imatinib therapy: A prospective multicenter real-world study.**
First Author: Xiangfei Sun, DrPH
- Board E12** **Abstract 122: A retro-prospective study to determine the patterns of recurrence in gastric and GE junction cancers after curative intent treatment at a tertiary cancer centre of North India.**
First Author: Abrar Rasool Khanday, DM
- Board E13** **Abstract 123: Long-term outcomes and patterns of recurrence in mucinous rectal adenocarcinoma: A KCRG multicenter study.**
First Author: Takumi Kozu, MD
- Board E14** **Abstract 124: A comparative analysis between clinicopathologic correlates of mismatch repair status compared to combined mismatch repair status and microsatellite instability in Filipino patients with colorectal cancer.**
First Author: Jonathan David Gorospe, MD
- Board E15** **Abstract 125: Host determinants of adjuvant chemotherapy feasibility and survival in localized upper gastrointestinal adenocarcinoma.**
First Author: Belinda Jiao, MD
- Board E16** **Abstract 126: Glucagon-like peptide-1 receptor agonists and risk of pancreatic cancer in high-risk individuals: A multicenter real-world analysis.**
First Author: Cho Han Chiang, MD, MSCI
- Board E17** **Abstract 127: Tumor mutation profiles and circulating tumor DNA detection across gastrointestinal and hepatobiliary cancers.**
First Author: Le-Tho T. Vo, BSc

- Board E18 Abstract 128: Treatment outcomes and prognostic factors in neuroendocrine carcinoma of the esophagus in Vietnam: A retrospective cohort study.**
First Author: Giang Thi Huong Nguyen, MD
- Board E19 Abstract 129: Sociodemographic disparities in pancreatic cancer incidence between 2000 and 2022: A Surveillance, Epidemiology and End Results analysis.**
First Author: Azmaeen Zarif, MA, MBBChir
- Board E20 Abstract 130: Assessing the impact of the COVID-19 pandemic on the diagnosis and staging of pancreatic cancer: A Surveillance, Epidemiology and End Results analysis.**
First Author: Azmaeen Zarif, MA, MBBChir
- Board F1 Abstract 131: Biomarker-independent real-world effectiveness and safety of toripalimab in advanced esophageal squamous cell carcinoma: A multicentre Indian experience.**
First Author: Rakesh Pinninti, MD, MBBS
- Board F2 Abstract 132: Real-world comparison of cabozantinib versus regorafenib as second-line therapy for advanced hepatocellular carcinoma after first-line immune checkpoint inhibitors: A propensity score-matched analysis.**
First Author: Shankar Biswas, MD
- Board F3 Abstract 133: Comparative real-world outcomes of durvalumab plus gemcitabine/cisplatin versus pembrolizumab plus gemcitabine/cisplatin as first-line therapy for advanced biliary tract cancer.**
First Author: Shankar Biswas, MD
- Board F4 Abstract 134: Fruquintinib versus trifluridine-tipiracil plus bevacizumab versus regorafenib in refractory metastatic colorectal cancer: A propensity score-matched real-world analysis.**
First Author: Shankar Biswas, MD
- Board F5 Abstract 135: Comparative effectiveness of first-line pembrolizumab plus chemotherapy, nivolumab plus chemotherapy, and nivolumab plus ipilimumab in metastatic esophageal squamous cell carcinoma: A propensity score-matched real-world analysis.**
First Author: Shankar Biswas, MD
- Board F7 Abstract 137: Systemic immune-inflammation index as a prognostic biomarker across T-stage, biliary obstruction, and treatment setting in cholangiocarcinoma: A retrospective cohort study.**
First Author: Naiyarat Prasongsook, MD, MS
- Board F8 Abstract 138: GLP-1 receptor agonist use and colorectal cancer risk in patients with inflammatory bowel disease.**
First Author: Sarina Ailawadi, DO
- Board F9 Abstract 139: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) versus statins and the risk of hepatocellular carcinoma (HCC) and hepatic decompensation in patients with type 2 diabetes mellitus (T2DM).**
First Author: Sarina Ailawadi, DO
- Board F10 Abstract 140: Multimodal prehabilitation and adherence to perioperative chemotherapy in localized gastroesophageal adenocarcinoma.**
First Author: Benjamin Gordon, MSc
- Board F11 Abstract 141: Targeted and immunotherapy strategies in biliary tract cancer: A Bayesian network meta-analysis comparing efficacy and safety.**
First Author: Siti Nurluthfia Rachmi
- Board F12 Abstract 142: Machine learning-based prediction of ICU mortality in patients with pancreatic cancer: A MIMIC-IV retrospective cohort study.**
First Author: Shankar Biswas, MD
- Board F13 Abstract 143: Molecular classification of biliary tract cancer by RNA clustering analysis and its clinicopathological characteristics.**
First Author: Yuta Maruki, MD
- Board F14 Abstract 144: Environmental metal exposure patterns and health-related quality of life in northeast Indian gallbladder cancer patients: A metallomic clustering study.**
First Author: Christy Thomas, MPharm, BPharm
- Board F15 Abstract 145: Effect of curcumin on anti-tumor immune cell profiles in colorectal cancer patients receiving cytotoxic chemotherapy.**
First Author: Jonggwon Choi Jr, MD
- Board F16 Abstract 146: Prognostic role of mismatch repair status in stage II colon cancer at Ho Chi Minh City Oncology Hospital.**
First Author: Quy Nguyen, PhD
- Board F17 Abstract 147: Effect of cancer-neurons on cytotoxic NK cell exhaustion and immunotherapy resistance in gastric cancer via spatial ECM trapping and neuropeptide signaling.**
First Author: Xinchun Wu, MMM
- Board F18 Abstract 148: Endothelial glycocalyx disruption to promote colorectal carcinogenesis and recurrence through formation of TLS-deficient immune microenvironment.**
First Author: Masahide Endo, MD
- Board F19 Abstract 149: Clinical characteristics and mutation status of KRAS, NRAS, and BRAF genes in stage IV colorectal cancer patients at Hanoi Medical University Hospital.**
First Author: Linh Ly Tran, MD, MSc
- Board F20 Abstract 150: PIK3CA alterations in metastatic colorectal cancer.**
First Author: Vivienne Lea, FRCPA
- Board G1 Abstract 151: Histopathological and clinicoradiological correlation in esophageal neoplasm and 2-year institutional experience in minimally invasive surgery.**
First Author: Gautam Anand, MCh, MBBS, MS
- Board G2 Abstract 152: Effect of sex-related non-immune cell crosstalk in the tumor microenvironment on skeletal muscle loss in colorectal cancer.**
First Author: Yu-Ru Guo, PhD

- Board G3** **Abstract 153: Effect of the FGF1-B promoter on spontaneous beta-cell tumorigenesis in F1B-Tag mice: A robust translational model for insulinoma and metabolic crosstalk.**
First Author: NaiXin Gu
- Board G5** **Abstract 155: Yttrium-90 resin microsphere transarterial radioembolization in unresectable hepatocellular carcinoma: Early results with scout dose-based lung shunt estimation and dosimetry.**
First Author: Jasim Jaleel, MD, DNB, MBBS
- Board G6** **Abstract 156: Perioperative analgesic approaches in hepatobiliary cancer malignancies: Experience from a tertiary care centre.**
First Author: Surabhi Sandill Sr
- Board G7** **Abstract 157: Effect of long-limb Roux-en-Y reconstruction on early glycemic control compared with Billroth II after subtotal gastrectomy in patients with type 2 diabetes and gastric cancer: 6-Month interim analysis of the STARDOM trial.**
First Author: Yeongkeun Kwon, MD
- Board G8** **Abstract 294: Comparative effectiveness of different interventions in metastatic melanoma: A network meta-analysis.**
First Author: Sami Salahia, MD, MSc
- Board G9** **Abstract 295: Hepatic arterial infusion chemotherapy combined with transcatheter chemoembolization, camrelizumab, and apatinib for BCLC stage C hepatocellular carcinoma: A retrospective study.**
First Author: Wang Xue
- Board G10** **Abstract 296: Adebrelimab plus TACE and/or HAIC for primary liver cancer: A retrospective study.**
First Author: Ruipeng Zheng
- Board G11** **Abstract 297: Lactate metabolic reprogramming based on LOX/LDHi-Cu NP to enhance copper death in hepatocellular carcinoma cells.**
First Author: Jiashuo Li, MD
- Board G12** **Abstract 298: Spatial multi-omics analyses to reveal KRT5+ tumor cell orchestration of an immune-excluded microenvironment in thymic carcinoma.**
First Author: Yixiang Zhang
- Board G13** **Abstract 299: Associations of multiple dietary indices with health outcomes and diet-related greenhouse gas emissions in U.S. adults: Evidence from NHANES 2005–2018.**
First Author: Vy Nguyen, MPH
- Board G15** **Abstract 301: Hepatic arterial infusion chemotherapy combined with transcatheter chemoembolization, camrelizumab, and apatinib for hepatocellular carcinoma with portal vein tumor thrombosis: A retrospective study.**
First Author: Su-Yang Xue
- Board G16** **Abstract 302: Decision-making in cancer during pregnancy: Real-world management patterns and outcomes from Nepal.**
First Author: Poonam Lama, MD
- Board G17** **Abstract 303: Divergence between expected and observed national cancer mortality after the COVID-19 pandemic: A population-based analysis.**
First Author: Mohammad Ahsen Soomro
- Board G18** **Abstract 304: Olanzapine-based, dexamethasone-free antiemetic prophylaxis for highly emetogenic chemotherapy in children and adolescents: A multicenter phase III non-inferiority trial (CIVIC-POD).**
First Author: Venkatraman Radhakrishnan, MD, MBBS, MSc, DM
- Board G19** **Abstract 305: A randomized, open-label, phase II trial of short-term combination pharmacotherapy in patients receiving cytotoxic chemotherapy for solid tumors.**
First Author: Beulah Elizabeth Koshy III, DM
- Board G20** **Abstract 306: A two-step pre-treatment screening strategy combining enzyme phenotyping and targeted DPYD genotyping: A pragmatic approach for preventing fluoropyrimidine toxicity.**
First Author: Joshua John Uzagare, MD, MBBS
- Board H1** **Abstract 307: Mechanistically guided therapeutic strategy for BAP1 mutant tumors through protein stability and chromatin modulation.**
First Author: Jing Han Hong, PhD
- Board H2** **Abstract 308: Synergistic oncogenesis in human cholangiocytes: IDH1 mutation and the biliary microenvironment to drive early transformation and a targetable metabolic dependency in patient-derived organoids.**
First Author: Ziye Chen
- Board H3** **Abstract 309: Hallmarks based stratification of locally advanced GBC according to response to first-line chemotherapy in advanced gallbladder cancer (GBC).**
First Author: Sushma Agrawal, MD
- Board H4** **Abstract 310: Serum laminin γ 2 monomer (LG2m) to reflect a CD90-driven immunosuppressive niche and survival benefit from atezolizumab plus bevacizumab in hepatocellular carcinoma.**
First Author: Kouki Nio
- Board H5** **Abstract 311: SGLT-2 inhibitors and heart failure outcomes in cancer patients and survivors: An updated systematic review and meta-analysis.**
First Author: Shabih Raza Farista, MBBS
- Board H6** **Abstract 312: Effects of sodium-glucose cotransporter 2 inhibitors on mortality and heart failure hospitalization in patients with cancer and diabetes mellitus: An updated systematic review and meta-analysis.**
First Author: Mazhar Ali, MBBS
- Board H7** **Abstract 356: Kaposi's Sarcoma in patients exposed to calcineurin inhibitors or systemic corticosteroids: A two-decade real-world safety assessment.**
First Author: Sara Abualinin

12:10-13:30

Trials in Progress Poster Session A: Gastrointestinal Cancers

Level 4, Canning Ballroom

Posters by Topic

Gastrointestinal Cancer

- Immunotherapies: H8, H9
- Multimodality Treatments: H10

Board H8 Abstract TPS158: Camrelizumab plus rivoceranib as first-line maintenance therapy after camrelizumab-chemo induction in advanced esophageal squamous cell carcinoma: A prospective, single-arm, phase II clinical trial.

First Author: Na Song

Board H9 Abstract TPS159: Tislelizumab combined with standard therapy for conversion treatment in patients with MSS, initially unresectable colorectal cancer liver metastases (CRLM): A prospective, phase II study.

First Author: Ying Yuan, MD, PhD

Board H10 Abstract TPS160: MC220404 coordinated nivolumab and intraperitoneal IL-2 for gastric cancer with peritoneal metastasis (CONTROL) phase 1b pilot study.

First Author: Mojun Zhu, MD

12:25-13:40

Poster Session B: Genitourinary Cancers, Hematologic Malignancies, Lung Cancer, Quality of Care

Level 4, Canning Ballroom

Posters by Topic

Genitourinary Cancer

- Advanced Disease: A1, A2
- Antibody Drug Conjugates: A3
- Early Detection and Surveillance: A4, A5
- Immunotherapies: A6-A8
- Multimodality Treatments: A9
- Omics for Precision Medicine: A10
- Real-World Evidence/Real-World Data: A11, A12, B1-B3
- Symptoms, Toxicities, and Whole-Person Care: B4, B5
- Tumor Biology, Biomarkers, and Pathology: B6-B8, C1
- Other Therapeutic Intervention: C2

Hematologic Malignancies

- Advanced Disease: C3
- Health Care Economics: C4
- Immunotherapies: C6-C7
- Models of Care and Care Delivery: C8, C9
- Omics for Precision Medicine: C10
- Real-World Evidence/Real-World Data: C11, C12, D1-D5
- Targeted Therapies: D6, D7
- Technology and Innovations: D8, D9
- Translational Research: D10

Lung Cancer

- Advanced Disease: D11
- Diagnostics: D12-D14
- Early Detection and Surveillance: D16
- Immunotherapies: E1-E4
- Novel Preclinical Models: E5
- Real-World Evidence/Real-World Data: E6-E14
- Targeted Therapies: E15-E18
- Technology and Innovations: E19, E20
- Tumor Biology, Biomarkers, and Pathology: F1, F2

Quality of Care

- Early Detection and Surveillance: F3
- Health Care Economics: F4, F5
- Immunotherapies: F6
- Models of Care and Care Delivery: F7-F20
- Palliative Care: G1-G8
- Prevention and Screening: G9, G10
- Real-World Evidence/Real-World Data: G11-G16
- Symptoms, Toxicities, and Whole-Person Care: G17-G19
- Technology and Innovations: G20, H1
- Telehealth/Telemedicine/Telecare: H2
- Other Therapeutic Intervention: H3

Board A1 Abstract 177: Long-term survival analysis of TNT: A phase II study of neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma.
First Author: Ting Xue

Board A2 Abstract 178: Neoadjuvant toripalimab combined with TIP chemotherapy for locally advanced penile squamous cell carcinoma: A multicenter prospective, single-arm, phase II clinical trial.
First Author: Ting Xue

Board A3 Abstract 179: Site-specific conjugation of PEG12-PSMA ligand to dianthin by click chemistry to kill prostate cancer cells in the presence of the endosomal escape enhancer SO1861.
First Author: Kasun Madusanka Rajamanthilage, PhD

Board A4 Abstract 180: A non-invasive lncRNA biomarker model for detection and metastatic risk prediction in prostate cancer.
First Author: Poonima Verma, PhD

Board A5 Abstract 181: Early results from a phase 1/2 clinical study of a urine-based multi-cancer early detection (MCED) assay for prostate, bladder, and kidney cancers.
First Author: Kenneth Chen, FRCS, MBBS, MRCS

Board A6 Abstract 182: Fibroblast growth factor receptor 3 (FGFR3) alterations and response to immune checkpoint inhibition in metastatic urothelial carcinoma: A systematic review and meta-analysis.
First Author: Oliver Oey, MD

Board A7 Abstract 183: Integrative immune-genomic profiling for identification of treatment-relevant phenotypes association with predicted sensitivity to neoadjuvant chemo-immunotherapy in muscle-invasive bladder cancer.
First Author: Onyekachi Anya, MBBS

Board A8 Abstract 184: Comparative efficacy and safety of first-line systemic combinations for advanced urothelial carcinoma: A Bayesian network meta-analysis.
First Author: Rahul Falodia

Board A9 Abstract 185: Predictive value of clinical complete response to neoadjuvant chemotherapy in trimodality therapy for muscle invasive bladder cancer.
First Author: Bharath Kumar, MD

Board A10 Abstract 186: Ultra-specific high-multiplex PCR liquid biopsy assays to enable high-frequency treatment and disease monitoring in urothelial malignancies.
First Author: Ilan Leibovitch, MD

Board A11 Abstract 187: Real-world outcomes and prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with advanced urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab (EVP).
First Author: Samad Sayed

Board A12 Abstract 188: Dose modifications, toxicity, and survival with enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): Real-world experience in Alberta, Canada.
First Author: Samad Sayed

Board B1 Abstract 189: Mortality trends and disparities in bone-metastatic prostate cancer in the United States, 1999–2024: A CDC WONDER analysis.
First Author: Vishan Das, MBBS

Board B2 Abstract 190: Association of higher thermal dose with improved 5-year recurrence-free survival after locoregional hyperthermia combined with intravesical chemotherapy for non-muscle-invasive bladder cancer.
First Author: Paola Tello Valverde, MSc

- Board B3** **Abstract 191: Health related quality of life (HRQOL) and early clinical outcomes of high - very high risk prostate cancer treated with linac based stereotactic body radiotherapy (SBRT) and long term androgen deprivation therapy (ADT).**
First Author: Jay Prakash Sahu, MD
- Board B4** **Abstract 192: Rapid and reversible endothelial glycocalyx injury during tyrosine kinase inhibitor therapy in locally advanced or metastatic renal cell carcinoma.**
First Author: Naoki Fujita, MD, PhD
- Board B5** **Abstract 193: Testosterone deprivation or androgen receptor inhibition effect on endothelial glycocalyx injury in prostate cancer.**
First Author: Naoki Fujita, MD, PhD
- Board B6** **Abstract 194: Beyond PSA and PSMA: Defining PSA–PSMA discordance for FDG PET and genomic stratification in mCRPC.**
First Author: Teenu Kamboj, MBBS
- Board B7** **Abstract 195: A ferroptosis-suppressive tumor state to drive chemoradiotherapy resistance and define a therapeutic vulnerability in muscle-invasive bladder cancer.**
First Author: Takuya Tsujino, MD, PhD
- Board B8** **Abstract 196: Assessing the clinical and biological associations between multimodal artificial intelligence (MMAI) and 22-gene genomic classifier (GC) in localized prostate cancer (PCa).**
First Author: Boon Hao Hong, MS
- Board C1** **Abstract 197: Genomic enrichment using Decipher and PAM50 luminal B to optimize neoadjuvant immunotherapy strategies in high-risk prostate cancer.**
First Author: Dimple Chakravarty
- Board C2** **Abstract 198: A novel oncolytic vaccinia virus armed with IL-21 and 4-1BBL for intravesical treatment of NMIBC: Preclinical efficacy and first-in-human safety evaluation.**
First Author: Shun Zhang
- Board C3** **Abstract 245: Single-cell analysis and functional profiling to reveal Galectin-3–driven reprogramming of the tumor immune microenvironment in transformed follicular lymphoma.**
First Author: Xiaohui Wang, MD
- Board C4** **Abstract 246: Polatumumab-R-CHP vs R-CHOP in older DLBCL: Survival benefit, infectious toxicity, and cost implications in middle-income health systems.**
First Author: Findy Prasetyawaty, MD
- Board C6** **Abstract 248: Daratumumab in the frontline management of newly diagnosed multiple myeloma: An overview of systematic reviews and meta-analyses.**
First Author: Riddhi Solanki, MHA, MPH, MSc
- Board C7** **Abstract 249: Identification of independent prognostic factors in relapsed pediatric B-ALL patients receiving CD19 CAR-T without consolidative HSCT.**
First Author: Ning Wang, MD
- Board C8** **Abstract 250: LEN-EOS study: Lenalidomide-associated eosinophilia as a marker of response to induction therapy in multiple myeloma.**
First Author: Abhijith P B, MD, DNB, MBBS
- Board C9** **Abstract 251: Impact of a structured, nurse-led transitional care model on self-efficacy and unplanned readmissions in patients receiving sequential CAR-T therapy for lymphoma.**
First Author: Chen Zheng, BS
- Board C10** **Abstract 252: Revolutionizing AML MRD: Gene-level kinetics to uncover chemoresistant clones and predict relapse risk via NGS.**
First Author: Moin Makda
- Board C11** **Abstract 253: Second primary malignancy risk in Hodgkin lymphoma survivors in the modern treatment era: A SEER MP-SIR analysis, 2000–2022.**
First Author: Tapan Ramesh Giri, MBBS
- Board C12** **Abstract 254: Early molecular kinetics to predict deep molecular response and inform frontline TKI selection in pediatric chronic myeloid leukemia: A real-world multicenter study.**
First Author: Wenbin An
- Board D1** **Abstract 255: Real-world experience with second and third generation tyrosine kinase inhibitors in imatinib-resistant Nigerian patients with BCR::ABL1 positive chronic myeloid leukaemia.**
First Author: Ibrahim Oluwaseun Ahmed, MD, MBBS, FMCPATH
- Board D2** **Abstract 256: Predictive scoring systems for molecular response assessment in pediatric chronic-phase chronic myeloid leukemia.**
First Author: Xingchen Wang
- Board D3** **Abstract 257: Heart failure-related mortality in leukemia patients: A 26-year United States surveillance study (1999–2024).**
First Author: Muhammad Hassan Ashraf Rai
- Board D4** **Abstract 258: Clinical features and long-term outcome in children and adolescents with non-Hodgkin lymphoma: A report of the Taiwan Pediatric Oncology Group study TPOG-NHL-2010.**
First Author: Yi-Lun Wang, MD
- Board D5** **Abstract 259: The impact of end-of-consolidation measurable residual disease in the era of novel pediatric leukemia therapy.**
First Author: Yi-Lun Wang, MD
- Board D6** **Abstract 260: Novel triplet combination of orelabrutinib, lenalidomide, and rituximab as frontline therapy for mantle cell lymphoma: Final results of POLARIS multicenter phase II study.**
First Author: Huilai Zhang
- Board D7** **Abstract 261: Proteolysis-targeting chimera (PROTAC) to target Bruton tyrosine kinase (BTK) degradation in mantle cell lymphoma.**
First Author: Xiaohui Wang, MD
- Board D8** **Abstract 262: Machine learning-based ICU mortality prediction across hematologic malignancy subtypes: A comparative analysis using MIMIC-IV.**
First Author: Shankar Biswas, MD

- Board D9** **Abstract 263: Machine learning prediction of clinical tumor lysis syndrome in critically ill patients with hematologic malignancies using laboratory trajectory features: A MIMIC-IV retrospective cohort study.**
First Author: Shankar Biswas, MD
- Board D10** **Abstract 264: TGFβ-mediated overexpression of podoplanin serves as a potential diagnostic biomarker in acute promyelocytic leukemia.**
First Author: Syed Hasan
- Board D11** **Abstract 265: Efficacy and safety of intrathecal pemetrexed in the treatment of leptomeningeal metastases from ALK-mutant NSCLC: A prospective, multi-center, single-arm, phase II clinical trial.**
First Author: Xiaowei Song
- Board D12** **Abstract 266: PET-based radiomics as a preoperative predictor of pathologic lymph node metastasis in lung cancer.**
First Author: Wei-Chih Shen
- Board D13** **Abstract 267: TP53–EGFR co-mutation landscape in Indian NSCLC: Decoding the genomic blueprint for targeted therapeutic decisions.**
First Author: Vasanthkumar Muthukumar, PhD, MSc
- Board D14** **Abstract 268: Real-time breath volatile organic compound analysis to detect newly diagnosed lung cancer.**
First Author: Prabhpreet Kaur
- Board D16** **Abstract 270: Association of a high-speed, knowledge-based AI tool at the primary care level with zero-miss triage and detection of incidental pulmonary nodules.**
First Author: Long Jiang, MD, PhD, MBBS
- Board E1** **Abstract 271: Adebrelimab plus apatinib for maintenance treatment of extensive-stage small cell lung cancer after first-line induction with addebrelimab plus chemotherapy (CLOG2402-ADAPT): A multi-center, single-arm, phase II trial.**
First Author: Lingyun Zhang, MD
- Board E2** **Abstract 272: Glycosylation signature to predict response to immune checkpoint blockade in lung cancer.**
First Author: Amanda Guo
- Board E3** **Abstract 273: Impact of smoking status on the efficacy of first-line immune checkpoint inhibitors in Asian patients with advanced non-small cell lung cancer: A meta-analysis.**
First Author: Raghda Mateen, MBBS
- Board E4** **Abstract 274: EBV DNA dynamics guide post-local-therapy ICI consolidation in stage II-III pulmonary lymphoepithelioma-like carcinoma.**
First Author: Minjie Chen
- Board E5** **Abstract 275: Shared tumor-reactive T cell clonotypes from tumor-infiltrating lymphocytes and tumor-associated lymph nodes defined by single-cell sequencing and tumor organoid models in non-small cell lung cancer.**
First Author: Yin Li, MD
- Board E6** **Abstract 276: Cross-continental transportability of phase III trial results to LMIC cohort with locally advanced NSCLC: A g-computation analysis with layered decomposition.**
First Author: Kratika Bhatia, DNB
- Board E7** **Abstract 277: Real-world outcomes of first-line afatinib in advanced non–small cell lung cancer patients with uncommon EGFR mutations at Vietnam National Cancer Hospital.**
First Author: Anh Tuan Nguyen, MD
- Board E8** **Abstract 278: Real-world efficacy of cabozantinib in combination with pemetrexed and carboplatin followed by pemetrexed-cabozantinib maintenance as first-line therapy for metastatic KRAS-mutant lung adenocarcinoma.**
First Author: Vivek Agarwala, MD, DNB, MBBS, DM, MRCP
- Board E10** **Abstract 280: Blinded ¹⁸F-FDG PET-CT re-read versus EBUS-TBNA in stage IIIA-C NSCLC: A mediastinal staging concordance study.**
First Author: Kratika Bhatia, DNB
- Board E11** **Abstract 281: Real-world efficacy and safety of first-line durvalumab combined with platinum–etoposide in extensive-stage small cell lung cancer: A single-center experience in Vietnam.**
First Author: Kien Hung Do, MD
- Board E12** **Abstract 282: Real-world comparative effectiveness and safety of sotorasib versus adagrasib in previously treated KRAS G12C-mutant non-small cell lung cancer: A propensity score-matched cohort study.**
First Author: Shankar Biswas, MD
- Board E13** **Abstract 283: Real-world comparative safety of first-line lorlatinib versus alectinib in metastatic ALK-rearranged non-small cell lung cancer: A propensity score-matched analysis.**
First Author: Shankar Biswas, MD
- Board E14** **Abstract 284: Real-world effectiveness and safety of amivantamab plus chemotherapy versus chemotherapy alone in EGFR-mutant NSCLC after osimertinib: A propensity score–matched analysis.**
First Author: Shankar Biswas, MD
- Board E15** **Abstract 285: Real-world comparison of carboplatin–pemetrexed–bevacizumab versus chemo-immunotherapy in EGFR-mutated lung cancer.**
First Author: Tadashi Nishimura, MD
- Board E16** **Abstract 286: Interaction of DLL3-targeting CAR-T cells with the JAK1 inhibitor in treating small cell lung cancer.**
First Author: Mengwei Li, MD, PhD
- Board E17** **Abstract 287: Multi-omics profiling of tumor DNA, mRNA, and plasma ctDNA in advanced lung cancer.**
First Author: Thien-Phuc Hoang Nguyen, MSc
- Board E18** **Abstract 288: Treatment outcomes with first-line EGFR tyrosine kinase inhibitors in Vietnamese metastatic NSCLC patients harboring compound EGFR mutations.**
First Author: Hoang Bao Ngoc, MD

- Board E19 Abstract 289: Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC: A Delphi study by the Asian Thoracic Oncology Research Group (ATORG).**
First Author: Aaron C. Tan, PhD, FRACP, MBBS
- Board E20 Abstract 290: H&E 3.0: An AI-driven, chemical-free virtual histology solution to enable worldwide multiomics profiling.**
First Author: Ruisi Li
- Board F1 Abstract 291: Tri-marker model integrating BCL2A1 expression in CD8⁺ T cells, PD-L1, and HOT score as a predictor of immune checkpoint blockade response in lung adenocarcinoma: A multi-cohort integrative analysis.**
First Author: Hoang Minh Quan Pham, MD, MS
- Board F2 Abstract 292: Prognostic value of the pre-treatment systemic inflammation response index (SIRI) for progression-free survival in EGFR-mutant advanced lung adenocarcinoma.**
First Author: Dang Huu Hai Tran, MD
- Board F3 Abstract 315: Strengthening nurse-led clinical breast examination (CBE) screening through quality improvement: A prospective implementation study from a tertiary hospital in eastern India.**
First Author: Kahkasha, MD, MBBS
- Board F4 Abstract 316: Understanding the impact of the Cancer Drug List on clinicians' prescription patterns in Singapore: A qualitative study.**
First Author: Mahendran Karnagaran
- Board F5 Abstract 317: New and more drugs for early-stage cancers: Have they translated to more cures?**
First Author: Laure-Anne Marie Nicole Teuwen, MD, PhD
- Board F6 Abstract 318: Real-world incidence and spectrum of immune-related toxicity in cancer patients: A registry cohort data from a Central Coast Cancer Centre.**
First Author: Dmitrii Shek
- Board F7 Abstract 319: Evaluating a hybrid AI-powered digital health guide to improve informed decision making and streamline access to genetic testing for hereditary cancer.**
First Author: Anita Kinney, PhD, RN
- Board F8 Abstract 320: A study of quality of life and unmet needs in young adult cancer.**
First Author: Disha Sawhney, PhD, MHA
- Board F9 Abstract 321: Calendar-year seasonality in colorectal and breast cancer screening and first-time uptake: A 6-year single-center time-series to optimize capacity level-loading (2020–2025).**
First Author: An-Ni Chen
- Board F10 Abstract 322: Beating the clock: Immunotherapy timing, early immune modulation, and clinical outcomes in hepatocellular carcinoma.**
First Author: Abhijith P B, MD, DNB, MBBS
- Board F11 Abstract 323: Quantitative hazard visualization of radioisotope contamination risks in emergency settings following radium-223 therapy.**
First Author: Soichi Makino
- Board F12 Abstract 324: Impact of a comprehensive multidisciplinary tumor board program on treatment decision-making and patient compliance in a tertiary care hospital in Thailand.**
First Author: Wimolrat Decha, MN
- Board F13 Abstract 325: Association of oncology education through virtual engagement with gender and geographic disparities: A global longitudinal analysis (2022–2025).**
First Author: Yan Leyfman, MD
- Board F14 Abstract 326: Impact of nurse-initiated early telephone follow-up on unplanned 30-day hospital admissions after first-cycle chemotherapy: A real-world implementation study.**
First Author: Pimsiri Aksornrung, BSN, BN
- Board F15 Abstract 327: National cancer control plans in Southeast Asia: A systematic comparison.**
First Author: Adrian E. Go, MD
- Board F16 Abstract 328: Impact of second-opinion pathology review process on diagnostic accuracy in sarcoma: Experience from the NTUH Center of Excellence for Sarcoma.**
First Author: Tom Wei-Wu Chen, MD, PhD
- Board F17 Abstract 329: Availability and reimbursement of systemic therapies for the five most common cancers in Vietnam: A national landscape analysis.**
First Author: Giang Hoang Pham, MD
- Board F18 Abstract 330: Psychosocial distress and health-related quality of life in women undergoing active treatment for breast and gynaecological cancers: A cross-sectional analysis.**
First Author: Ankur Bahl, MD, MBBS
- Board F19 Abstract 331: From the outback to oncology suites: Redefining cancer care for rural and Aboriginal Australians.**
First Author: Mathew George
- Board F20 Abstract 332: Patient, caregiver and provider perspectives on cancer treatment adherence in Singapore: A qualitative study.**
First Author: Chin-Wen Chong, BA
- Board G1 Abstract 333: Efficacy of psychological intervention in children with cancer: A randomized controlled trial.**
First Author: Ruqayya Manzoor, FCPS, MBBS
- Board G2 Abstract 334: Bridging critical disparities: A telementoring approach to equitable palliative care in Malaysia.**
First Author: Aishah Ashari, MBBSCh
- Board G3 Abstract 335: Place of death patterns among patients with renal cell carcinoma in the United States: A 24-year nationwide analysis.**
First Author: Cher Ying Foo, MD

- Board G4** **Abstract 336: Real-world insights of patterns of palliative and end-of-life care in patients with advanced cancer: LMIC single-center wake-up call.**
First Author: Hafsa Thabassum, DM
- Board G6** **Abstract 338: Last Departure: A nurseled innovation to standardize and humanize endoflife care in oncology.**
First Author: Suwanna Rinchai, BSN
- Board G7** **Abstract 339: Admission-day predictors of terminal outcome in advanced cancer inpatients: Insights from a large Indian palliative care cohort.**
First Author: Allwin Jesuraj, MBBS
- Board G8** **Abstract 340: Circadian rhythm of mortality among hospitalized cancer patients: A retrospective study.**
First Author: Meimei Shang
- Board G9** **Abstract 341: Training tomorrow's oncologists: Impact of the oncology interest group at the Benemérita Universidad Autónoma de Puebla during the 3rd Oncology Congress in Mexico sponsored by ASCO.**
First Author: Nimbe Sánchez Camela, BM
- Board G10** **Abstract 342: Detecting is living: Evaluation and promotion of oncological knowledge in medical students through the incorporation of exploration workshops, an initiative led by the Oncology Student Interest Group of the Benemérita Universidad Autónoma de Puebla endorsed by ASCO.**
First Author: Jesús Antonio Alcántara Palma, MD
- Board G11** **Abstract 343: Clinical and radiologic outcomes of immune checkpoint inhibitor therapy in cancer patients with pre-existing interstitial lung disease: A retrospective study from Vietnam.**
First Author: Thao Ninh Thi, MD
- Board G12** **Abstract 344: Liver resection in a resource-limited setting: Outcome of developed-world standards of R0 resection and 30-day mortality without a dedicated ICU or advanced technology—A real-world data analysis from Sri Lanka.**
First Author: Sampath Hirantha Herath, MD, MBBS
- Board G13** **Abstract 345: Postoperative ICU outcomes and predictors of morbidity and mortality in cancer patients after oncosurgery: A retrospective study from a tertiary care center in India.**
First Author: Mehak Sharma
- Board G14** **Abstract 346: Expectations and unmet needs of cancer patients seeking Ayurved Rasayana therapy: A cross-sectional study from India.**
First Author: Yogesh Narayan Bendale, MD
- Board G15** **Abstract 347: Racial and ethnic disparities in hospital mortality among cancer patients admitted to the intensive care unit: A retrospective analysis of the MIMIC-IV database.**
First Author: Shankar Biswas, MD
- Board G16** **Abstract 348: Cancer mortality rates by educational attainment among U.S. adults aged 25–64 years: A population-based analysis (2021–2023).**
First Author: Mohammad Ahsen Soomro
- Board G17** **Abstract 349: The impact of malnutrition on chemotherapy toxicity and quality of life in advanced breast cancer patients.**
First Author: Andree Kurniawan, MD
- Board G18** **Abstract 350: Patient-reported outcomes for effective screening of chemotherapyinduced peripheral neuropathy.**
First Author: Gowri Shivasabesan, MBBS
- Board G19** **Abstract 351: Validation and feasibility of symptom management toolkit among cancer survivors and caregivers in India.**
First Author: Deepak Saini
- Board G20** **Abstract 352: Implementation of a patient-reported symptom tool in low-resource settings with high demand for services: A pilot feasibility study (PROMISE-Pilot).**
First Author: Jayson L. Co, MD, MSc
- Board H1** **Abstract 353: Real-world artificial intelligence use in oncology practice: High clinician verification amid critical governance gaps.**
First Author: Yan Leyfman, MD
- Board H2** **Abstract 354: Latent profiles of digital health technophobia and associated factors among older adults with cancer.**
First Author: Yingtao Meng
- Board H3** **Abstract 355: Comparison of double lung versus single lung ventilation in prone thoracoscopic esophagectomy for esophageal cancer: A multicenter cohort study.**
First Author: Jayanth Yoganathan

Friday, June 26

12:25-13:40

**Trials in Progress Poster Session B: Genitourinary Cancers,
Lung Cancer**

Level 4, Canning Ballroom

Posters by Topic

Lung Cancer

- Advanced Disease: H6

Board H6

Abstract TPS293: Adebrelimab combined with oral etoposide for older patients and patients with poor performance status In small cell lung cancer: A multicenter, open-label, phase II clinical study.

First Author: Fang Liu

12:10-13:30

Poster Session C: Breast Cancer, Developmental Therapeutics, Genetics/Genomics/Multiomics, Gynecologic Cancer, Head and Neck Cancer

Level 4, Canning Ballroom

Posters by Topic

Breast Cancer

- Antibody Drug Conjugates: A1
- Early Detection and Surveillance: A2
- Immunotherapies: A3, A4
- Local Disease: A5
- Models of Care and Care Delivery: A6, A7
- Omics for Precision Medicine: A8
- Real-World Evidence/Real-World Data: A9-A12, B1-B8
- Symptoms, Toxicities, and Whole-Person Care: C1-C7
- Targeted Therapies: C8-C10
- Technology and Innovations: C11
- Tumor Biology, Biomarkers, and Pathology: C12, D1-D4

Developmental Therapeutics

- Immunotherapies: D7-D9
- Multimodality Treatments: D10
- Real-World Evidence/Real-World Data: D11
- Targeted Therapies: D12-D14
- Translational Research: D15
- Vaccines: D16

Genetics/Genomics/Multiomics

- Diagnostics: E1
- Early Detection and Surveillance: E2
- Health Care Economics: E3, E4
- Omics for Precision Medicine: E5-E7
- Prevention and Screening: E8-E10
- Real-World Evidence/Real-World Data: E11, E12
- Tumor Biology, Biomarkers, and Pathology: E13, E14, E16

Gynecologic Cancer

- Advanced Disease: E17
- Diagnostics: E18-E20
- Early Detection and Surveillance: F1-F3
- Immunotherapies: F4-F7
- Models of Care and Care Delivery: F8
- Omics for Precision Medicine: F9
- Real-World Evidence/Real-World Data: F10-F13
- Symptoms, Toxicities, and Whole-Person Care: F14
- Tumor Biology, Biomarkers, and Pathology: F15-F17

Head and Neck Cancer

- Advanced Disease: F18, F19
- Immunotherapies: F20, G1, G2
- Models of Care and Care Delivery: G3-G5
- Multimodality Treatments: G6
- Real-World Evidence/Real-World Data: G7-G10
- Symptoms, Toxicities, and Whole-Person Care: G11
- Targeted Therapies: G12
- Tumor Biology, Biomarkers, and Pathology: G13-G16

Board A1 Abstract 30: Comparative efficacy and safety of sacituzumab govitecan versus chemotherapy in metastatic breast cancer: An updated meta-analysis and systematic review.

First Author: Mohammad Dawar Zahid, MBBS

Board A2 Abstract 31: Prospective study of quantitative broadband diffuse optical spectroscopy for differential diagnosis of suspicious breast lesions.

First Author: Alice Marie Police

Board A3 Abstract 32: Targeting tumoral CXCL3 in triple-negative breast cancer: Association with tumor vasculature and immune surveillance.

First Author: Suboj Babykutty, PhD

Board A4 Abstract 33: Doxycycline modulation of the CD39/CD73–adenosine axis to enhance CD8⁺ T cell and M1 macrophage immunity in patient-derived breast cancer samples.

First Author: Parameswar Dalai, DPhil

Board A5 Abstract 34: Anthracycline-free platinum-based neoadjuvant chemotherapy in operable triple-negative breast cancer: Interim analysis of pathologic complete response rates and predictors of response.

First Author: Evgeniya Ratova

Board A6 Abstract 35: Barriers and facilitators of shared decision-making for pregnancy after breast cancer: A qualitative study of patients and healthcare professionals.

First Author: Jeonghee Ahn, PhD

Board A7 Abstract 36: Contraceptive awareness and practice in breast cancer cases across the cancer care continuum: A mixed method research.

First Author: Shailley Arora Sehgal, DMRT, DNB

Board A8 Abstract 37: Association of tumor microenvironment landscape with neoadjuvant therapy resistance in hormone receptor–positive breast cancer.

First Author: Zhen Wang, MD, PhD

Board A9 Abstract 38: Early toxicity–driven dose modification and efficacy of adjuvant abemaciclib in high-risk HR+/HER2– early breast cancer: A real-world study in Chinese patients.

First Author: Jing Huang

Board A10 Abstract 39: Questioning the benefit of adjuvant chemotherapy in premenopausal HR+/HER2– early breast cancer: Real-world evidence from an Asian cohort.

First Author: Jen-Yu Chuang, MD

Board A11 Abstract 40: Clinicopathologic features, treatment patterns, and survival outcomes of glycogen-rich clear cell carcinoma of the breast: A National Cancer Database Analysis.

First Author: Cher Ying Foo, MD

Board A12 Abstract 41: Real-world treatment patterns and survival outcomes in acinic cell carcinoma of the breast: A National Cancer Database study.

First Author: Cher Ying Foo, MD

Board B1 Abstract 42: Performance of the hybrid tumor-informed and tumor-agnostic ctDNA testing to predict breast cancer recurrence and progression: A real-world study in Southeast Asia.

First Author: Anh Nguyen

Board B2 Abstract 43: Heart failure–related mortality in patients with breast cancer: A 26-year national surveillance study (1999–2024).

First Author: Muhammad Hassan Ashraf Rai

- Board B4** **Abstract 45: Comparative effectiveness of first-line ribociclib plus aromatase inhibitor versus palbociclib plus aromatase inhibitor in HR+/HER2– metastatic breast cancer: A global real-world evidence study.**
First Author: Shankar Biswas, MD
- Board B5** **Abstract 46: Real-world comparative safety and survival of alpelisib-fulvestrant versus capivasertib-fulvestrant in HR+/HER2– metastatic breast cancer: A propensity score–matched analysis.**
First Author: Shankar Biswas, MD
- Board B6** **Abstract 47: Diagnostic accuracy of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients: A single-institutional experience.**
First Author: Balasubramanian Venkitaraman, MCh
- Board B8** **Abstract 49: CanAssist Breast in routine clinical care: A real-world single-centre experience.**
First Author: Rajeev Kumar
- Board C1** **Abstract 50: Effectiveness and safety of traditional Chinese medicine external wash combined with local cooling in preventing UTD1-induced peripheral neuropathy in breast cancer patients: A single-arm, phase II preliminary study.**
First Author: Xiaojia Wang, MD, PhD
- Board C2** **Abstract 51: Disproportionality analysis of musculoskeletal and connective tissue disorders associated with aromatase inhibitors: A real-world pharmacovigilance study.**
First Author: Jeong-Hwa Yoon, PhD
- Board C3** **Abstract 52: Efficacy of dance-based interventions on psychosocial outcomes and fatigue in breast cancer survivors: A systematic review and meta-analysis.**
First Author: Melisha Koirala, MBBS
- Board C4** **Abstract 53: Efficacy of exercise-based interventions for the management of chemotherapy-induced peripheral neuropathy in patients with breast cancer: A systematic review and meta-analysis.**
First Author: Melisha Koirala, MBBS
- Board C5** **Abstract 54: Efficacy of perioperative esketamine on postoperative recovery in patients with breast cancer undergoing modified radical mastectomy: A systematic review and meta-analysis.**
First Author: Melisha Koirala, MBBS
- Board C6** **Abstract 55: Efficacy of melatonin supplementation for sleep quality, depression, and fatigue in patients with breast cancer: A systematic review and meta-analysis.**
First Author: Melisha Koirala, MBBS
- Board C7** **Abstract 56: Unmet needs, quality of life, and lived experiences of patients with metastatic breast cancer in central Viet Nam: A convergent mixed-methods study.**
First Author: Minh-Tri Phan, MD
- Board C8** **Abstract 57: Comparative PK/PD and efficacy data of liposomal doxorubicin and EXODS (bio-engineered exosomes loaded with doxorubicin) in metastatic triple-negative breast cancer.**
First Author: Abhishek Dutta
- Board C9** **Abstract 58: Choosing the optimal neoadjuvant backbone for HER2-positive breast cancer: A multicenter real-world comparison of AC-THP and TCHP in Vietnam.**
First Author: Thai Hong Le, MD
- Board C10** **Abstract 59: The AI–CDK4/6i synergy matrix: A denovo metaanalysis decoupling aromataseinhibitor identity from survival outcomes in 1L HR+/HER2– advanced breast cancer.**
First Author: Divyanshu Prajapati
- Board C11** **Abstract 60: Breast cancer mHealth apps across treatment and survivorship: A systematic review of directly evaluated content and features.**
First Author: Jessica Gonzalez, DNP, MS, MSN
- Board C12** **Abstract 61: Integrated analysis of miRNA–mRNA regulatory crosstalk: Insights from the miR-296-3p and DDHD2 network in breast cancer.**
First Author: Ruqia Mehmood Baig, PhD
- Board D1** **Abstract 62: Subtype-specific cell-surface glycoalyx–associated molecular expression programs revealed by public single-cell RNA sequencing in breast cancer.**
First Author: Emiri Sugiyama, MD
- Board D2** **Abstract 63: Axillary lymph node metastasis status and associated factors in patients with breast cancer undergoing radical surgery.**
First Author: Pham Dang Thuyen
- Board D3** **Abstract 64: Analytical cross-sectional study of correlation between plasma D-dimer levels and lymphovascular invasion in operable carcinoma breast.**
First Author: Pradeep Balineni, MBBS
- Board D4** **Abstract 65: Targeting human neuropeptide Y1 receptor (NPY1R) using a monoclonal antibody that targets an extracellular epitope.**
First Author: Arezoo Sadeghi Vardanjani, MSc
- Board D7** **Abstract 79: CAR-NK cell therapy in colorectal cancer: A systematic review of early clinical signals and translational strategies.**
First Author: Muhammad Alifian Remifita Putra, MD, MSc
- Board D8** **Abstract 80: Tumor NK ligand profiles as predictors of allogenic NK cell therapy responsiveness.**
First Author: Nam Tran
- Board D9** **Abstract 81: Tofacitinib for immune-related adverse events \geq grade 3 induced by immune checkpoint inhibitors: A single-arm, open-label, two-stage study.**
First Author: Jing Lin

- Board D10 Abstract 82: ICTriplex (chemotherapy + immune checkpoint inhibition + targeted therapy) in advanced/refractory malignancies: A personalized treatment program.**
First Author: Philip A. Salem, MD
- Board D11 Abstract 83: Autoimmune cytopenias associated with immune checkpoint inhibitors: A disproportionality analysis of FAERS.**
First Author: Ratnadeep Biswas
- Board D12 Abstract 84: Investigating the roles of JUP, HMGB1, and FASN knockdown using pro-siRNA mediated regulation on TRAIL and TNF- α induced apoptosis.**
First Author: Tarra Theodora Tjandra, MS
- Board D13 Abstract 85: Anisamide-conjugated PLGA nanoparticles for targeted co-delivery of sorafenib and paclitaxel in colorectal cancer.**
First Author: Madhunika Agrawal, PhD, MSc
- Board D14 Abstract 86: Targeted delivery of topotecan via folic acid functionalized phycocyanin nanoparticles for ovarian cancer.**
First Author: Satyam Kumar Agrawal, PhD, MSc
- Board D15 Abstract 87: VEGF suppression via exon 2 splice-switching Vivo-Morpholino antisense oligo to inhibit tumor growth in a mouse subcutaneous model.**
First Author: Shan Jiang, PhD
- Board D16 Abstract 88: Identification of novel CD8+ immune epitopes relevant for EBV-related cancers.**
First Author: Aarshiya Jain
- Board E1 Abstract 161: Clinical significance of germline BRCA pathogenic variants undetectable by comprehensive genomic profiling.**
First Author: Shiho Hakui, ND
- Board E2 Abstract 162: Germline landscape of pancreatic cancer in Singapore and dual architecture of DNA repair and pancreatitis-associated gene variants: Implications for population-tailored testing.**
First Author: Nur Diana Ishak
- Board E3 Abstract 163: Upfront 69-gene next-generation sequencing versus reflex PCR in BCR::ABL1-negative myeloproliferative neoplasms: Diagnostic yield, prognostic impact, and cost analysis in an Indian cohort.**
First Author: Moin Makda
- Board E4 Abstract 164: Cost-effectiveness of population screening for Lynch syndrome and hereditary breast and ovarian cancer syndrome in Singapore.**
First Author: Sara Tasnim, BPharm, MSc
- Board E5 Abstract 165: Structural modelling of germline FOXA1 variants identified in Asian participants with incident gastrointestinal cancers from the UK Biobank.**
First Author: Shirin Hui Tan, BPharm
- Board E6 Abstract 166: Genomic profiling of adolescent and young adult cancers in Asia: A scoping review.**
First Author: Neil Bhargava, MBBS
- Board E7 Abstract 167: Characterizing plasma circulating tumor RNA (ctRNA) landscape in advanced NSCLC: Preliminary insights into treatment resistance and tumor microenvironment.**
First Author: Michelle Pek, PhD
- Board E8 Abstract 168: Family-based cascade screening in hereditary breast and ovarian cancer: Identification of asymptomatic carriers and a 15-year window for risk reduction.**
First Author: Pratibha Yadav
- Board E9 Abstract 169: Real-world validation of a Lynch syndrome screening model in a multi-ethnic Asian cohort with dMMR tumors.**
First Author: Mengyuan Yang
- Board E10 Abstract 170: Clinically actionable cancer and non-cancer risk genes identified by whole genome sequencing (WGS) in early-onset tumours (EOT).**
First Author: Milita Zaheed, FRACP, MMed
- Board E11 Abstract 171: Genetic spectrum of cancer susceptibility: Insights from a 6,093-patient real-world cohort in Singapore.**
First Author: Mengyuan Yang
- Board E12 Abstract 172: Impact of concurrent liquid and tissue NGS in advanced NSCLC: Real-world insights from an Indian single-centre study.**
First Author: Ankur Bahl, MD, MBBS
- Board E13 Abstract 173: The link between methylation age acceleration and incidence of brain glioblastoma: Two-sample bidirectional and multivariable Mendelian randomization analyses.**
First Author: Jehad Yasin
- Board E14 Abstract 174: Single-cell atlas and the role of sex hormones and chromosomes in sex-divergent reprogramming of the tumor microenvironment.**
First Author: Ning Kang
- Board E16 Abstract 176: A single-cell multi-omic atlas of extrahepatic cholangiocarcinoma progression with ST6GAL1-enriched preinvasive states.**
First Author: Siming Kong
- Board E17 Abstract 203: Divergent long-term burden trajectories and mortality drivers of female-specific cancers in the United States.**
First Author: Ze Jin, MD, DM
- Board E18 Abstract 204: Preoperative prediction of p53abn endometrial cancer molecular subtype using a T2-weighted MRI radiomics fusion model: A multi-center study.**
First Author: Chengyang Luo
- Board E19 Abstract 205: Diagnostic performance of the IOTA SR xCA-125 model in predicting ovarian malignancy in women undergoing surgery for adnexal masses.**
First Author: Garima Yadav, MD
- Board E20 Abstract 206: Real-world genomic profiling of endometrial cancer in south India to identify clinically actionable alterations.**
First Author: Vasanthkumar Muthukumar, PhD, MSc

- Board F1** **Abstract 207: Prediction model for recurrence and metastasis of cervical cancer after surgery using machine learning.**
First Author: Bingbing Zhao, MD
- Board F2** **Abstract 208: Development and validation of a prognostic model to independently predict cervical cancer recurrence using the immunophenotyping profiles in peripheral blood.**
First Author: Bingbing Zhao, MD
- Board F3** **Abstract 209: Structural determinants of diagnosis and prognosis in cervical cancer: Associations between care setting, comorbidity burden, and sociodemographic factors.**
First Author: Jessica Moore, MD
- Board F4** **Abstract 210: Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer.**
First Author: Yulu Wang
- Board F5** **Abstract 211: Penpulimab plus anlotinib as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A multicentre, single-arm, phase II trial.**
First Author: Haifeng Qiu
- Board F6** **Abstract 212: Efficacy and safety of immune checkpoint inhibitors in recurrent platinum-resistant ovarian cancer: A systematic review and meta-analysis of randomized controlled trials.**
First Author: Aakash Pandit, MBBS
- Board F7** **Abstract 213: Comparative efficacy and safety of first-line maintenance therapies in advanced ovarian cancer: A biomarker-stratified Bayesian network meta-analysis of 16 phase 3 trials.**
First Author: Rahul Falodia
- Board F8** **Abstract 214: Survivorship care planning and psychosocial outcomes in cervical cancer caregivers.**
First Author: Priyadarshini Mari, MD
- Board F9** **Abstract 215: Curcumin analogues and HMOX1-mediated ferroptosis in endometrial cancer.**
First Author: Xiangxiang Wu, MD
- Board F10** **Abstract 216: Prognostic value of pretreatment systemic immune-inflammation index towards tumor response in patients with locally advanced cervical cancer treated with definitive radiotherapy in Indonesia.**
First Author: Yoga Dwi Oktavianda, MD
- Board F11** **Abstract 217: Trends in gynaecological cancer incidence in Singapore over the last two decades.**
First Author: Hui Miao, PhD
- Board F12** **Abstract 218: First-line maintenance olaparib in a low-body mass index Asian population with advanced ovarian cancer: Real-world outcomes from a Vietnamese cohort.**
First Author: Long Thanh Nguyen, MD, MSc
- Board F13** **Abstract 219: Stage distribution and survival outcome in a real-world cervical cancer cohort from an urban-dominant population in Indonesia.**
First Author: Vito Filbert Jayalie, MD
- Board F14** **Abstract 220: Predictors of post-operative morbidity and mortality after debulking surgeries for gynecological malignancies.**
First Author: Juhi Sharma
- Board F15** **Abstract 221: MicroRNA-197-3p to counteract chemoresistance in ovarian cancer via COL4A6 inhibition.**
First Author: Yi-Hui Wu, PhD
- Board F16** **Abstract 222: Circulating tumor cell-based molecular classification to reveal heterogenous subclones in gestational trophoblastic neoplasia.**
First Author: Xin Hong
- Board F17** **Abstract 223: TMEM132A to promote cervical cancer progression via HOMER3-mediated activation of FAK/PI3K/AKT signaling pathway.**
First Author: Fengyi Sun
- Board F18** **Abstract 224: A prospective study comparing response and toxicity with or without nimotuzumab in concurrent chemoradiotherapy in locally advanced head and neck cancer.**
First Author: Manoj Kumar Mahana Jr, MD, MBBS
- Board F19** **Abstract 225: Comparative study of efficacy, toxicity, and tumor regression of nano-docetaxel+platinum+5FU vs +capecitabine in LA-HNSCC.**
First Author: Manjula Beck, MD
- Board F20** **Abstract 226: Tislelizumab in combination with carboplatin and albumin-binding paclitaxel for neoadjuvant therapy in head and neck squamous cell carcinoma: A prospective, phase II clinical study.**
First Author: Haotian Cao, PhD, MB
- Board G1** **Abstract 227: An oral anlotinib-capecitabine regimen plus penpulimab as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, phase 2 clinical trial.**
First Author: Cheng Xu, MD
- Board G2** **Abstract 228: Effect of VAV1 on metastasis and immune evasion in squamous cell carcinoma.**
First Author: Taonong Cai
- Board G3** **Abstract 229: Treatment timelines, care delivery gaps, and their impact on outcomes in postoperative radiotherapy for head and neck cancer.**
First Author: Samarпита Mohanty, MD
- Board G4** **Abstract 230: Comprehensive geriatric assessment to predict 30-day postoperative morbidity in elderly patients undergoing curative surgery for oral squamous cell carcinoma: A prospective observational study.**
First Author: Anoop Attakkil, MBBS, MS

- Board G5 Abstract 231: Learning from failure: A multifactorial analysis of locoregionally advanced laryngeal cancer (LALC) recurrence and the impact of a standardized SOP in a resource-limited setting.**
First Author: Bhaskar Chakraborty, MD, FCPS
- Board G6 Abstract 232: Stereotactic body radiotherapy combined with chemotherapy and PD-1 inhibitor in oligometastatic nasopharyngeal carcinoma (STOMP): A prospective phase II clinical trial.**
First Author: Jingjing Miao, MD, PhD, MBBS, MSc, MMed
- Board G7 Abstract 233: Prognostic impact of pathological skin and bone invasion in buccal mucosa squamous cell carcinoma.**
First Author: Krupa Vakharia
- Board G8 Abstract 234: Perioperative predictors of outcomes in head and neck cancer surgery: A prospective observational analysis.**
First Author: Pushplata Gupta, MD
- Board G9 Abstract 235: Perioperative factors associated with adverse outcomes in head and neck cancer surgery with free flap reconstruction: A sub-analysis of the HANCOS trial.**
First Author: Pushplata Gupta, MD
- Board G10 Abstract 236: Real world outcomes with neoadjuvant chemo-immuno-metronomic therapy in advanced head and neck squamous cell carcinoma (NeoLOCUS-Retro).**
First Author: Joshua John Uzagare, MD, MBBS
- Board G11 Abstract 237: Functional outcomes and quality of life after partial glossectomy for tongue carcinoma: A prospective observational study.**
First Author: Gautam Anand, MCh, MBBS, MS
- Board G12 Abstract 238: Nimotuzumab combined with induction chemotherapy and concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A prospective, multicenter, randomized controlled trial—Preliminary analysis.**
First Author: Chen Xi Shan
- Board G13 Abstract 239: SPP1⁺ macrophage influence on differentiation of radioiodine-refractory thyroid cancer through secretion of FABP4.**
First Author: Zhenyu Luo
- Board G14 Abstract 240: Prognostic significance of undetectable baseline HPV circulating tumor DNA in oropharyngeal cancer.**
First Author: Justin Albert Fortino, BS
- Board G16 Abstract 242: Innate immune cross-talk of glioblastoma pathophysiology: Understanding NLRP3 and NLRP12.**
First Author: Sushmita Rajkhowa, MSc

12:10-13:30

Trials in Progress Poster Session C: Breast Cancer, Developmental Therapeutics, Head and Neck Cancer

Level 4, Canning Ballroom

Posters by Topic

Breast Cancer

- Symptoms, Toxicities, and Whole-Person Care: G17-G19

Developmental Therapeutics

- Immunotherapies: G20, H1, H2

Head and Neck Cancer

- Local Disease: H3
- Technology and Innovations: H4

Board G17 Abstract TPS66: BRIGHT-Fe: A phase III randomized trial of intravenous ferric derisomaltose vs low-dose oral iron polypeptide in iron-deficient early breast cancer receiving (neo)adjuvant chemotherapy.

First Author: Rakesh Pinninti, MD, MBBS

Board G18 Abstract TPS67: Impact of SPECT/CT lymphoscintigraphy-based radiotherapy planning for reducing incidental dose to arm draining lymph nodal region vs standard planning on lymphedema incidence in early breast cancer patients post BCS: A double blind randomized controlled trial.

First Author: Aashish Joshy Jr, MBBS

Board G19 Abstract TPS68: Acute skin toxicity comparison of adjuvant two-weekly accelerated hypofractionated versus three-weekly moderately hypofractionated radiotherapy in breast cancer: A phase 2, open label, randomized control trial.

First Author: Aswathi PL Jr, MBBS

Board G20 Abstract TPS89: Translational advancement of HCB101, a third-generation SIRPα–Fc ligand trap targeting the CD47-SIRPα axis: Integrated phase 1 monotherapy and phase 1b/2a combination development.

First Author: Fangling Ning

Board H1 Abstract TPS90: Tri-specific immune checkpoint engineering: Clinical translation of HCB301 targeting SIRPα, PD-L1, and TGF.

First Author: Ji Zhu, MD

Board H2 Abstract TPS91: Phase 1 dose escalation of ACM-CpG, a polymersome-delivered TLR9 agonist for advanced solid tumors after prior treatment with checkpoint inhibitor.

First Author: Amit Jain

Board H3 Abstract TPS243: The ELIMINATE trial: A phase II/III randomized trial evaluating omission of radiotherapy to regional lymphatics in pN0/N1 neck for oral cavity carcinomas.

First Author: Aman Sharma, MD

Board H4 Abstract TPS244: The HYPCON 3 Trial: A phase II/III randomized study evaluating hypo-fractionated accelerated versus conventional fractionated adjuvant radiation therapy in head and neck malignancies.

First Author: Aman Sharma, MD

Exhibitor Directory

Fairmont Ballroom Foyer

The exhibits are open on Thursday from 07:45-17:00 and Friday from 07:45-18:00 in the Fairmont Ballroom Foyer.

The most up-to-date list of exhibitors and a floor plan highlighting the location of each exhibitor can be found online at breakthrough.asco.org.

The Exhibitor Directory provides oncologists and other health care professionals with information about companies and their products and services. The Exhibitor Directory does not represent endorsement by American Society of Clinical Oncology ("ASCO"), either express or implied, of any exhibitor, product, or service. ASCO does not make any warranty concerning the accuracy or reliability of any information contained in this directory and ASCO disclaims any and all responsibility for and liability relating to all such information. The use of the name, logo, or marks of ASCO is strictly prohibited without the prior written consent of ASCO. The information contained in this directory may not be used in any way with or without reference to ASCO's name, logo, or marks without the prior written consent of ASCO.

If an exhibitor scans your badge, you are sharing your contact data with the exhibitor, and you consent to be contacted by the exhibitor. If you have questions about how an exhibitor uses data, please contact the exhibitor or see their privacy policy.

© denotes Conquer Cancer, the ASCO Foundation, Donor and/or Conquer Cancer Council Member as of May 13, 2026.

**Information listed below is current as of May 8, 2026.*

AbbVie ©
abbvie.com

Amgen ©
amgen.com

ASCO®
asco.org
Stop by the ASCO table in the Exhibits area to save on your ASCO membership! Representing more than 50,000 oncology professionals, ASCO unites the global oncology community to conquer cancer by turning groundbreaking science into life-saving care. Through trusted research, world-class meetings, and career-long support, we empower members across all disciplines to advance innovation, improve patient outcomes, and create a world where cancer is prevented or cured, and every survivor is healthy.

AstraZeneca ©
astrazeneca-us.com

BeOne Medicines ©
beonemed.com

BioNTech ©
biontech.com/de/de/home.html

Gene Tools, LLC
gene-tools.com

GSK ©
gsk.com

Janssen Biotech, Inc. ©
jnj.com

Moderna Therapeutics ©
moderntx.com

MSD ©
msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world's most challenging diseases.

PMV Pharma ©
pmvpharma.com

Revolution Medicines ©
revmed.com

Roche Singapore Pte Ltd. ©
roche.com